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METHODS FOR INHIBITING CLC-2 
CHANNEL WITH GATX2 
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US2007 /073325 filed with the U.S. Receiving Office of the 
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ority to and benefit ofU.S. Provisional PatentApplicationNo. 
60/831,110 filed on Jul. 14, 2006, by Nae! McCarty, Chris-
topher H. Thompson, and Julia Kubanek, and where permis-
sible is incorporated herein in their entirety. 
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FIELD OF THE INVENTION 
2 
useful as tools for studying the permeation pathways and/or 
gating mechanisms of anion channels. 
Venoms from snakes, scorpions, marine snails, and spiders 
are rich sources of peptide ligands that have proven to be of 
5 great value in the functional exploration of cation channels. 
Peptide ligands have proven to be among the most potent and 
selective antagonists available for voltage-gated channels 
permeable to K+, Na+, and Ca2 +, and have been very useful 
tools for detailed structural analysis of these proteins. Pore-
lO blocking toxins provide clues about the arrangement of chan-
nel domains, about the interactions between the permeant 
ions and the pore, and about the proximity and interactions of 
the gating machinery with the pore. Gating modifiers provide 
15 tools to dissect the processes underlying the transitions 
between gating states. Peptide ligands have high potential as 
lead compounds for the development of therapeutics target-
ing pain, diabetes, multiple sclerosis, cardiovascular dis-
eases, and cancer. Because peptide ligands have well-defined 
20 structures, constrained by disulfide bridges, they bind with 
much higher affinity and specificity than other blockers avail-
able to date, and report the structures of their targets at 
molecular detail. Unfortunately, no peptide toxins have been 
isolated that inhibit a CIC channel. 
25 Therefore, it is an object to provide CIC channel ligands 
and methods of their use. 
It is another object to provide peptide compositions that 
block or inhibit c1- channels. 
It is yet anotherobject to provide peptide compositions that 
30 block or inhibit c1- channels for the manufacture of a medi-
cament. 
It is anotherobjectto provide pharmaceutical peptide com-
positions for modulating chloride ion channels. 
Aspects of the invention are generally related to composi- 35 
tions and methods of modulating chloride channel activity, 
for example using peptide ligands isolated from scorpion 
It is still anotherobject to provide methods for treating CIC 
channel-related disorders with peptide inhibitors ofion chan-
nels. 
venom. SUMMARY OF THE INVENTION 
BACKGROUND OF THE INVENTION 40 
Compositions containing CIC channel ligands and meth-
ods of their use are provided. In one aspect, the CIC channel 
ligand is a scorpion venom peptide having at least 97%, 98%, 
99% or 100% sequence identity to 1VSCEDCPDHC-
45 STQKARAKCDNDKCVCEPI29 (SEQ ID NO: !)(also 
referred to as GaTx2). Variants and derivatives of the peptide 
ligand are also provided. The peptide ligand is believed to 
have a molecular mass of about 3.2 kDa and Kn of about 12 
Chloride-conducting ion channels of the CIC family have 
important roles in a host of biological processes. These poly-
topic membrane proteins form aqueous pathways through 
which anions are selectively allowed to pass down their con-
centration gradients. The Cl Cs are found in nearly all organ-
isms, with members in every mammalian tissue, yet relatively 
little is known about their mechanism or regulation. It is clear, 
however, that they are fundamentally different in molecular 
construction and mechanism from the well-known potas- 50 
sium-, sodium-, and calcium-selective channels. 
µM for CIC-2 at -100 m V. 
In another aspect, the peptide ligand is isolated from Leiu-
rus quinquestriatus hebraeus venom. 
CIC channels play roles as diverse as cell volume regula-
tion, renal salt reabsorption, controlling resting potential in 
excitable cells, and regulation of endosomal pH. Some Cl Cs 
are broadly expressed; therefore, their disruption by mutation 
or knockout can have serious physiological consequences. 
For example, all but one of the nine CIC family members is 
expressed in the kidney. A c1- channel gene is the locus of the 
primary defect in several human diseases. Mutations in genes 
encoding CIC channels are involved in generalized epilepsy, 
Bartter's syndrome, Dent's disease (a form of bone disorder 
due to improper handling of calcium by the kidney), myoto-
nia, and osteopetrosis. Despite their central roles in many 
physiological processes, our understanding of the structures 
and mechanisms of anion-permeable channels has lagged far 
behind that of their cation-permeable peers. One clear reason 
for this discrepancy is a paucity of specific probes that may be 
Still another aspect provides a method for reducing CIC 
channel activity by contacting the CIC channel with the dis-
closed CIC channel ligands. 
55 Still another aspect provides a method of reducing chloride 
transport through a chloride channel by contacting the chlo-
ride channel with the polypeptide ligand. 
Yet another aspect provides a method for treating a disorder 
60 or symptoms of a disorder related to aberrant chloride chan-
nel activity by administering a therapeutically effective 
amount of the polypeptide ligand. The disorder can be 
selected from the group consisting of cancer, cystic fibrosis, 
epilepsy, renal tubular disorders, Bartter's syndrome, Dent's 
65 disease, myotonia, osteopetrosis, Angleman or Prader-Willi, 
upregulation of chloride channels in glioma cells, diarrhea-
predominant inflammatory bowel syndrome, autosomal 
US 8,324,158 B2 
3 
dominant polycystic kidney disease (ADPKD), excitotoxic 
neuronal injury, and secretory diarrhea. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-D show representative (reversed phase) 
RP-HPLC chromatograms of Lqh pf-venom (partially-frac-
tionated venom) (A) or active fractions (B, C). The area 
included in the gray boxes, or indicated by an arrow, contains 
the active fraction or peak. The elution gradient is represented 
by a dashed line. The right panel presents summary data for 
fraction activity. Bars show mean±SEM for 3-10 observa-
tions. The inset shows representative traces from Two-elec-
trode Voltage Clamp (TEVC) experiments in the absence 
(black trace) or presence (gray trace) of the active fractions or 
isolated peak at V M=-160 m V following a step from -30 m V. 
(D). Dose-response curve from a single TEVC experiment for 
inhibitionofCIC-2 atV M=-160mVby0.01, 0.1, 1, or lOnM 
native toxin. Inset shows dose-response plotted on a log scale. 
FIG. 2A is a line graph showing MALDI-MS analysis of 
peak 3. 
FIG. 2B shows the sequence aligmnent ofGaTx2 (SEQ ID 
NO: 1) with other previously identified, highly related toxins 
(Leiuropeptide II (SEQ ID N0:6), Leiuropeptide III (SEQ ID 
N0:7), Neurotoxin POI (SEQ ID NO:S), OdKl (SEQ ID 
N0:9), Leiuropeptide I (SEQ ID NO: 10), Maurotoxin (SEQ 
ID NO: 11 and Scyllatoxin (SEQ ID NO: 12). Disulfide bridge 
connectivity (specifically for GaTx2) is shown below the 
sequence alignment, while the predicted secondary structure 
for GaTx2 is shown above the sequence. 
FIG. 2C shows a homology model ofGaTx2 (middle) with 
the NMR structures of Scyllatoxin (left) and Chlorotoxin 
(right), in three orientations. The top panel shows disulfide 
bridges in bond representation. 
4 
toxin, indicating that no post-translational modifications 
were associated with the native toxin other than the three 
disulfide bonds. 
FIGS. 6A and 6B show line graphs and bar graphs of 
5 current data showing that GaTx2 does not inhibit ShB-IR K+ 
channel currents, Kvl.2 K+ channel currents, or currents 
mediated by GABAc receptor, CIC-1, or CIC-3 chloride 
channels. 
FIG. 6C shows line graphs and bar graphs of GABA cur-
10 rent data in the absence and presence of GaTx2. Comparison 
of current in the presence of 10 µM GABA to currents in the 
presence of 10 µM GABA plus 10 nM CGaTx2 showed no 
change (13±9.4% increase, p=0.32). GABA-induced c1- cur-
rents also did not increase upon removal of toxin from the 
15 bath solution (14±19% increase, p=0.74). This suggests that 
GaTx2 is not capable of inhibiting currents from GABAc 
receptors. 
FIG. 6D shows line graphs and bar graphs ofCIC-1 current 
data no inhibition of CIC-1 in the absence and presence of 
20 GaTx2. In the presence of 10 nM GaTx2, tail currents at 
V M=-120 mV from +60 mV were 1.036±0.012 fold larger 
than currents after washout of toxin, implying no inhibition of 
CIC-1. 
FIG. 6E shows line graphs and bar graphs ofCIC-3 current 
25 data in the absence and presence of GaTx2. 10 nM GaTx2 did 
not inhibit CIC-3 channel mediated currents. 
DETAILED DESCRIPTION OF THE INVENTION 
30 I. Definitions 
FIG. 3A is a multi-channel inside-out patch recording at 35 
V M=-100 mV of CIC-2 in the presence of control extracel-
lular solution (top), or 2 nM synthetic GaTx2 (bottom). The 
record at the left is from the beginning of the experiment, 
while the record at the right is from the end of the experiment, 
after the backfilled toxin had some time to diffuse to the patch 40 
at the tip of the electrode. 
The term "antibody" includes complete antibodies, as well 
as fragments thereof (e.g., F(ab')2 , Fab, etc.) and modified 
antibodies produced therefrom (e.g., antibodies modified 
through chemical, biochemical, or recombinant DNA meth-
odologies), with the proviso that the antibody fragments and 
modified antibodies retain antigen binding characteristics 
sufficiently similar to the starting antibody so as to provide for 
specific detection of antigen. 
By "antisense polynucleotide" is meant a polynucleotide 
having a nucleotide sequence complementary to a given poly-
nucleotide sequence including polynucleotide sequences 
associated with the transcription or translation of the given 
polynucleotide sequence (e.g., a promoter), where the anti-
sense polynucleotide is capable of hybridizing to a polynucle-
FIG. 3B is a dose-response curve for inhibition of CIC-2 
currents from multi-channel patches by GaTx2 at concentra-
tions of 2 pM, 20 pM, 200 pM, and 2 nM; V M=-100 m V. All 
points contain data from 6-17 measurements of window cur- 45 
rent at each concentration. 
FIG. 3C is a bar graph showing a comparison of inhibition 
of CIC-2 by 2 pM GaTx2 when currents were measured at 
V M=-60 or -100 m V, in multichannel patches as shown in 
FIG. 3A; * indicated p<0.001. 
FIG. 4A is a line graph of current versus number of events 
and shows GaTx2 does not change single-channel amplitude. 
All-points amplitude histograms in the absence (left) and 
presence (right) of 2 nM GaTx2. 
50 
FIG. 4B shows a representative single channel trace of 55 
CIC-2 with and without 20 µM synthetic toxin at V M=-100 
mV. 
FIG. 4C shows an expanded single channel trace ofa CIC-2 
burst in the absence and presence of 20 pM GaTx2. 
otide sequence. Of particular interest are antisense polynucle-
otides capable of inhibiting transcription and/or translation, 
either in vitro or in vivo. 
By "antivenom" is meant an antivenin or an antitoxin to a 
venom; or an antiserum containing such antitoxin. 
The term "biologically active" refers to CIC channel 
ligands having structural, regulatory, or biochemical func-
tions of a naturally occurring polypeptide. Likewise, "immu-
nologically active" defines the capability of the natural, 
recombinant or synthetic CIC channel ligand, or any oli-
gopeptide thereof, to induce a specific immune response in 
appropriate animals or cells and to bind with specific anti-
bodies. 
The term "CIC channel ligand" refers to a molecule or 
compound that interacts with a CIC channel. An exemplary 
FIG. 4D is a bar graph showing a comparison of channel 
activity (as NP dN) in the absence and presence of 20 pM 
GaTx2. 
FIG. 4E is a bar graph showing a comparison oflatency to 
opening of the first double-barreled burst after stepping from 
0 to -100 m V, in the absence and presence of 20 pM GaTx2. 
60 CIC channel ligand includes a polypeptide having at least 
97% sequence identity to SEQ ID NO: 1. The terms "scorpion 
venom polypeptide", "peptide toxin", "GaTx2", and "CIC 
channel ligand" are used interchangeably. The manimalian 
CIC family includes nine members including CIC-0, CC-1, 
FIGS. SA and SB are line graphs showing that the folded 
synthetic toxin shows the same mass as the purified native 
65 CIC-2, CIC-3, CIC-4, CIC5, CIC-6, CIC-Kl, and CIC-K2. 
"Coding sequence" refers to a nucleotide sequence that 
codes for a specific amino acid sequence. "Regulatory 
US 8,324,158 B2 
5 
sequences" refer to nucleotide sequences located upstream ( 5' 
non-coding sequences), within, or downstream (3' non-cod-
ing sequences) of a coding sequence, and which influence the 
transcription, RNA processing or stability, or translation of 
the associated coding sequence. Regulatory sequences may 
include promoters, translation leader sequences, intrans, and 
polyadenylation recognition sequences. 
6 
tide that is functionally equivalent to the recited polypeptide, 
e.g., polynucleotides that are degenerate variants, or poly-
nucleotides that encode biologically active variants or frag-
ments of the recited polypeptide. 
As used herein, the term "prodrug" refers to an active agent 
chemically transformed into a per se inactive derivative 
which, by virtue of chemical or enzymatic attack, is converted 
to the parent agent within the body before or after reaching the 
site of action. Prodrugs are frequently (though not necessar-
The term "derivative" as used herein refers to the chemical 
modification of a CIC channel ligand. Illustrative of such 
modifications would be replacement ofhydrogen by an alkyl, 
acyl, or amino group. A polypeptide derivative would retain 
essential biological characteristics of a natural polypeptide. 
10 ily) pharmacologically inactive until converted to the parent 
drug. A prodrug may be converted into the parent drug by 
various mechanisms, including enzymatic processes and 
metabolic hydrolysis. Examples of prodrugs include, but are 
not limited to, ester and amide prodrugs; polyethylene glycol 
The term "effective amount" or "therapeutically effective 
amount" means a dosage sufficient to provide treatment of the 
disease state being treated or to otherwise provide a desired 
pharmacologic and/or physiologic effect. The precise dosage 
will vary according to a variety of factors such as subject-
dependent variables (e.g., age, immune system health, etc.), 
the cause of the injury (e.g., the species of scorpion), the 
disease (e.g., the nature of the effect on CIC channels caused 20 
by the disease), and the treatment being effected. In the case 
15 prodrugs (with and without a linker); N-acyl amine prodrugs, 
dihydropyridine prodrugs, 2-hydroxybenzamide prodrugs; 
carbamate prodrugs; peptide prodrugs; Mannich bases, and 
Schiff bases. 
of a scorpion sting, an "effective amount" is that amount 
necessary to substantially improve the likelihood of treating 
the sting, in particular that amount which improves the like-
lihood of successfully preventing effects of the toxins on the 25 
subject, relieving or minimizing toxin effects, or arresting any 
complications caused or exacerbated by the toxin. Where the 
scorpion toxin is used as an insecticide or pesticide, an "effec-
tive amount" is that amount necessary to kill the insect or pest, 
or otherwise affect the behavior of the insect or pest in such a 30 
way that it no longer performs or causes undesired events or 
activities, e.g. consume or damage plants. 
By "envenomation" is meant when a subject is bitten or 
stung by a scorpion. 
The terms "individual," "host," "subject," and "patient" are 35 
used interchangeably herein, and refer to a mammal, includ-
ing, but not limited to, murines, simians, humans, mammalian 
farm animals, mammalian sport animals, and mammalian 
pets. 
As used herein the term "isolated" is meant to describe a 40 
"Protein Transduction Domain" or PTD refers to a 
polypeptide, polynucleotide, carbohydrate, or organic or 
inorganic compounds that facilitates traversing a lipid 
bilayer, micelle, cell membrane, organelle membrane, or 
vesicle membrane. A PTD attached to another molecule 
facilitates the molecule traversing membranes, for example 
going from extracellular space to intracellular space, or cyto-
sol to within an organelle. Exemplary PTDs include but are 
not limited to HIV TATYGRKKRRQRRR (SEQ. ID N0:2) 
or RKKRRQRRR (SEQ. ID N0.3); 11 Arginine residues, or 
positively charged polypeptides or polynucleotides having 
8-15 residues, preferably 9-11 residues. 
"Subjects" or "patients" as used herein, encompasses any 
subject or patient amenable to application of the methods of 
treatment or diagnostic methods. Mammalian subjects and 
patients, particularly human subjects or patients, are of par-
ticular interest. 
As used herein, the term "substantially purified" refers to a 
compound (e.g., either a polynucleotide or a polypeptide) that 
is removed from its natural environment and is at least 60% 
free, preferably 75% free, and most preferably 90% free from 
other components with which it is naturally associated. 
As used herein, the terms "treatment," "treating," and the 
like, refer to obtaining a desired pharmacologic and/or physi-
ologic effect. The effect may be prophylactic in terms of 
completely or partially preventing a symptom thereof and/or 
compound of interest (e.g., either a polynucleotide or a 
polypeptide) that is in an environment different from that in 
which the compound naturally occurs e.g. separated from its 
natural milieu such as by concentrating a peptide to a con-
centration at which it is not found in nature. "Isolated" is 
meant to include compounds that are within samples that are 
substantially enriched for the compound of interest and/or in 
which the compound of interest is partially or substantially 
purified. 
45 may be therapeutic in terms of a partial or complete cure for 
an adverse affect attributable to the condition. "Treatment," as 
used herein, covers any treatment of an injury in a mammal, 
particularly in a human, and includes: (a) preventing the 
injury, arresting any complications, and minimizing its 
50 effects; (b) relieving the symptoms; ( c) preventing the disease 
from occurring in a subject which may be predisposed to the 
disease but has not yet been diagnosed as having it; ( d) inhib-
iting the disease, i.e., arresting its development; and ( e) reliev-
"Polypeptide" as used herein refers to an oligopeptide, 
peptide, modified polypeptide, or protein. Where "polypep-
tide" is recited herein to refer to an amino acid sequence of a 
naturally-occurring protein molecule, "polypeptide" and like 
terms are not meant to limit the amino acid sequence to the 
complete, native amino acid sequence associated with the 55 
recited protein molecule, but is meant to encompass ana-
logues, degenerate substitutions, etc. 
ing the disease, i.e., causing regression of the disease. 
A "substantial portion" of an amino acid or nucleotide 
sequence refers to an amino acid or a nucleotide sequence that 
is sufficient to afford putative identification of the protein or 
gene that the amino acid or nucleotide sequence comprises. 
Amino acid and nucleotide sequences can be evaluated either 
"Polynucleotide" and "nucleic acid" as used interchange-
ably herein refer to an oligonucleotide, nucleotide, and frag-
ments or portions thereof, as well as to peptide nucleic acids 
(PNA), fragments, portions or antisense molecules thereof, 
and to DNA or RNA of genomic or synthetic origin which can 
be single- or double-stranded, and represent the sense or 
antisense strand. Where "polynucleotide" or "nucleic acid" is 
used to refer to a specific polynucleotide sequence (e.g. 
encoding a scorpion toxin such as GaTx2), the terms are 
meant to encompass polynucleotides that encode a polypep-
60 manually by one skilled in the art, or by using computer-based 
sequence comparison and identification tools that employ 
algorithms such as BLAST (Basic Local Alignment Search 
Tool; Altschul et al. (1993) J. Mal. Biol. 215:403-410). In 
general, a sequence of ten or more contiguous amino acids or 
65 thirty or more contiguous nucleotides is necessary in order to 
putatively identify a polypeptide or nucleic acid sequence as 
homologous to a known protein or gene. Moreover, with 
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respect to nucleotide sequences, gene-specific oligonucle-
otide probes comprising 30 or more contiguous nucleotides 
may be used in sequence-dependent methods of gene identi-
fication (e.g., Southern hybridization) and isolation (e.g., in 
situ hybridization of bacterial colonies or bacteriophage 
plaques). In addition, short oligonucleotides of 12 or more 
nucleotides may be used as amplification primers in PCR in 
order to obtain a particular nucleic acid fragment comprising 
the primers. Accordingly, a "substantial portion" of a nucle-
otide sequence comprises a nucleotide sequence that will 10 
afford specific identification and/or isolation of a nucleic acid 
fragment comprising the sequence. The instant specification 
involves amino acid and nucleotide sequences encoding 
polypeptides that comprise one or more particular scorpion 
toxin proteins. The skilled artisan, having the benefit of the 15 
sequences as reported herein, may now use all or a substantial 
portion of the disclosed sequences for purposes known to 
those skilled in this art. Accordingly, the instant invention 
comprises the complete sequences as reported in the accom-
panying Sequence Listing, as well as substantial portions of 20 
those sequences as defined above. 
As used herein, "substantially similar" refers to nucleic 
acid fragments wherein changes in one or more nucleotide 
bases results in substitution of one or more amino acids, but 
do not affect the functional properties of the polypeptide 25 
encoded by the polynucleotide sequence. "Substantially 
similar" also refers to modifications of the nucleic acid frag-
ments of the instant invention such as deletion or insertion of 
one or more nucleotides that do not substantially affect the 
functional properties of the resulting protein molecule. It is 30 
therefore understood that the invention encompasses more 
than the specific exemplary sequences. 
Moreover, substantially similar nucleic acid fragments 
may also be characterized by their ability to hybridize. Esti-
mates of such homology are provided by either DNA-DNA or 35 
DNA-RNA hybridization under conditions of stringency as is 
well understood by those skilled in the art (Hames and Hig-
gins, Eds. (1985) Nucleic Acid Hybridisation, IRL Press, 
Oxford, U.K.). Stringency conditions can be adjusted to 
screen for moderately similar fragments, such as homologous 40 
sequences from distantly related organisms, to highly similar 
fragments, such as genes that duplicate functional enzymes 
from closely related organisms. Post-hybridization washes 
determine stringency conditions. One set of preferred condi-
tions uses a series of washes starting with 6xSSC, 0.5% SDS 45 
at room temperature for 15 min, then repeated with 2xSSC, 
0.5% SDS at 45° C. for 30 min, and then repeated twice with 
0.2xSSC, 0.5% SDS at 50° C. for 30 min. A more preferred 
set of stringent conditions uses higher temperatures in which 
the washes are identical to those above except for the tern- 50 
perature of the final two 30 min washes in 0.2xSSC, 0.5% 
SDS was increased to 60° C. Another preferred set of highly 
stringent conditions uses two final washes in O.lxSSC, 0.1 % 
SDS at 65° C. 
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acid sequences reported herein. Most preferred are nucleic 
acid fragments that encode amino acid sequences that are at 
least about 95%, 98%, 99% or more identical to the amino 
acid sequences reported herein. 
II. CIC Channel Ligands 
A. Peptide Ligands 
It has been discovered that the toxin referred to as GaTx2 
binds to CIC channels and modulates chloride channel activ-
ity. GaTx2 was previously believed to be a K+ channel ligand 
based on homology to other toxins. One embodiment pro-
vides a toxin that has at least 97%, 98%, 99% or 100% 
sequence identity to VSCEDCPDHCSTQKARAKCDND-
KCVCEPI (SEQ ID NO: 1) a variant, derivative or prodrug 
thereof. GaTx2 is approximately a 3.2 kDa peptide with three 
disulfide bonds which hold together a secondary structure 
likely to be composed of one a-helix and two ~-strands. 
GaTx2 has an apparent dissociation constant of about 12 µM 
for CIC-2 at -100 mV. 
GaTx2 inhibits CIC-2 with higher affinity than any other 
available drug and, in fact, is the best inhibitor of any chloride 
channel. The previously best available CIC inhibitor, CPP, 
interacts with CIC-1 with a Kn of 15 µM, while GaTxl inhib-
its CFTR with a Kn of25 nM at-100 m V (Fuller, M. D., et al. 
(2007) Biophys. J. 92 Supplement, 275a, Abstract). 
The physiological role ofCIC-2 is still largely undefined. It 
is thought that CIC-2 may play a role in vascular smooth 
muscle cells and may be expressed on the apical membrane of 
epithelial cells along with CFTR, although this is still con-
troversial. GaTx2 will be useful in determining the role of 
CIC-2 in these cells and may aid in determining the mem-
brane localization of CIC-2 in specific cell types. Also, muta-
tions in CIC-2 have been implicated in epilepsy, while under-
activity of WT CIC-2 has been implicated in constipation-
associated inflanmiatory bowel disease, Therefore, GaTx2 
may serve as a lead compound for peptidomimetic drugs that 
target CIC-2. 
GaTx2 was isolated from the venom of Leiurus quinques-
triatus hebraeus, the giant Israeli scorpion. The peptide 
ligand binds to CIC channels, in particular chloride channels. 
In one embodiment, the CIC channel is CIC-2. 
Another embodiment provides a purified peptide isolated 
from the venom of Leiurus quinquestriatus hebraeus wherein 
the peptide interacts with chloride channels in a voltage 
dependent manner. 
B. Variants of CIC Channel Ligands 
1. Conservative Substitutions of Amino Acids 
Another embodiment provides nucleic acid molecules that 
encode a polypeptide having a conservative amino acid 
change, compared with SEQ ID NO: 1. For example, variants 
can be obtained that contain one or more amino acid substi-
tutions of SEQ ID NO: 1, in which an alkyl amino acid is 
substituted for an alkyl amino acid in a GaTx2 amino acid 
sequence, an aromatic amino acid is substituted for an aro-
matic amino acid in a GaTx2 amino acid sequence, a sulfur-
55 containing amino acid is substituted for a sulfur-containing 
amino acid in a GaTx2 amino acid sequence, a hydroxy-
containing amino acid is substituted for a hydroxy-containing 
amino acid in a GaTx2 amino acid sequence, an acidic amino 
acid is substituted for an acidic amino acid in a GaTx2 amino 
Substantially similar nucleic acid fragments may also be 
characterized by the percent identity of the amino acid 
sequences that they encode to the amino acid sequences dis-
closed herein, as determined by algorithms commonly 
employed by those skilled in this art. Suitable nucleic acid 
fragments (isolated polynucleotides of the present invention) 60 
encode polypeptides that are at least about 70% identical, 
preferably at least about 80% identical to the amino acid 
sequences reported herein. Preferred nucleic acid fragments 
encode amino acid sequences that are at least about 85% 
identical to the amino acid sequences reported herein. More 65 
preferred nucleic acid fragments encode amino acid 
sequences that are at least about 90% identical to the amino 
acid sequence, a basic amino acid is substituted for a basic 
amino acid in a GaTx2 amino acid sequence, or a dibasic 
monocarboxylic amino acid is substituted for a di basic mono-
carboxylic amino acid in a GaTx2 amino acid sequence. 
Among the common amino acids, for example, a "conserva-
tive amino acid substitution" is illustrated by a substitution 
among amino acids within each of the following groups: (1) 
glycine, alanine, valine, leucine, and isoleucine, (2) phenyla-
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lanine, tyrosine, and tryptophan, (3) serine and threonine, ( 4) 
aspartate and glutamate, (5) glutamine and asparagine, and 
( 6) lysine, arginine and histidine. The BLOSUM62 table is an 
amino acid substitution matrix derived from about 2,000 local 
multiple alignments of protein sequence segments, represent- 5 
ing highly conserved regions of more than 500 groups of 
related proteins (Henikoff and Henikoff, Proc. Nat'! Acad. 
Sci. USA 89:10915 (1992)). Accordingly, the BLOSUM62 
substitution frequencies can be used to define conservative 
amino acid substitutions that may be introduced into the 10 
amino acid sequences of the disclosed peptide ion channel 
inhibitors. Although it is possible to design amino acid sub-
stitutions based solely upon chemical properties (as discussed 
above), the language "conservative amino acid substitution" 
preferably refers to a substitution represented by a BLO- 15 
SUM62 value of greater than -1. For example, an amino acid 
substitution is conservative ifthe substitution is characterized 
by a BLOSUM62 value of 0, 1, 2, or 3. According to this 
system, preferred conservative amino acid substitutions are 
characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 20 
3), while more preferred conservative amino acid substitu-
tions are characterized by a BLOSUM62 value of at least 2 
(e.g., 2 or 3). 
Particular variants ofGaTx2 are characterized by having at 
least 70%, at least 80%, at least 90%, at least 95% or greater 25 
than 96% sequence identity to the corresponding amino acid 
sequence (e.g., SEQ ID NO:l), wherein the variation in 
amino acid sequence is due to one or more conservative 
amino acid substitutions. 
10 
are cultured in the absence of a natural amino acid that is to be 
replaced (e.g., phenylalanine) and in the presence of the 
desired non-naturally occurring amino acid(s) (e.g., 2-aza-
phenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 
4-fluorophenylalanine ). The non-naturally occurring amino 
acid is incorporated into the protein in place of its natural 
counterpart. See, Koide et al., Biochem. 33:7470 (1994). 
Naturally occurring amino acid residues can be converted to 
non-naturally occurring species by in vitro chemical modifi-
cation. Chemical modification can be combined with site-
directed mutagenesis to further expand the range of substitu-
tions (Wynn and Richards, Protein Sci. 2:395 (1993)). 
3. Non-Conservative Amino Acid Substitutions 
A limited number of nonconservative amino acids, amino 
acids that are not encoded by the genetic code, non-naturally 
occurring amino acids, and unnatural amino acids may be 
substituted for GaTx2 amino acid residues. 
Essential amino acids in the polypeptides can be identified 
according to procedures known in the art, such as site-di-
rected mutagenesis or alanine-scanning mutagenesis (Cun-
ningham and Wells, Science 244:1081 (1989), Bass et al., 
Proc. Nat'! Acad. Sci. USA 88:4498 (1991), Coombs and 
Corey, "Site-Directed Mutagenesis and Protein Engineer-
ing," in Proteins: Analysis and Design, Angeletti (ed.), pages 
259-311 (Academic Press, Inc. 1998)). In the latter technique, 
single alanine mutations are introduced at every residue in the 
molecule, and the resultant mutant molecules are tested for 
biological activity to identify amino acid residues that are 
critical to the activity of the molecule. See also, Hilton et al., 
"Conservative amino acid" variants can be obtained by 
oligonucleotide-directed mutagenesis, linker-scarming 
mutagenesis, mutagenesis using the polymerase chain reac-
tion, and the like (see Ausubel (1995) at pages 8-10 to 8-22; 
and McPherson (ed.), Directed Mutagenesis: A Practical 
Approach (IRL Press 1991)). A variant GaTx2 polypeptide 
can be identified by the ability to specifically bind anti-Ga Tx2 
antibodies. 
30 J. Biol. Chem. 271 :4699 (1996). 
2. Variants Containing Non-naturally Occurring Amino 
Acid Residues 
The disclosed peptide ligands can also comprise non-natu-
rally occurring amino acid residues. Non-naturally occurring 
amino acids include, without limitation, trans-3-methylpro-
line, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hy-
droxyproline, N-methylglycine, allo-threonine, methylthreo-
nine, hydroxyethylcysteine, hydroxyethylhomocysteine, 
nitroglutamine, homoglutamine, pipecolic acid, thiazolidine 
carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-
dimethylproline, tert-leucine, norvaline, 2-azaphenylalanine, 
3-azapheny !alanine, 4-azapheny !alanine, and 4-fluoropheny-
lalanine. Several methods are known in the art for incorpo-
rating non-naturally occurring amino acid residues into pro-
teins. For example, an in vitro system can be employed 
wherein nonsense mutations are suppressed using chemically 
aminoacylated suppressor tRNAs. Methods for synthesizing 
amino acids and aminoacylating tRNA are known in the art. 
Transcription and translation of plasmids containing non-
sense mutations is typically carried out in a cell-free system 
comprising anE. coli S30 extract and commercially available 
enzymes and other reagents. Proteins are purified by chroma-
tography. See, for example, Robertson et al., J. Am. Chem. 
Soc. 113:2722 (1991), Ellman et al., Methods Enzymol. 202: 
301 (1991), Chung et al., Science 259:806 (1993), and Chung 
et al., Proc. Nat'! Acad. Sci. USA 90:10145 (1993). 
In a second method, translation is carried out in Xenopus 
oocytes by microinjection of mutated mRNA and chemically 
aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. 
Chem. 271:19991 (1996)). Within a third method, E.coli cells 
Although sequence analysis can be used to further define 
the GaTx2 anion channel binding region, amino acids that 
play a role in GaTx2 binding activity (such as binding of 
GaTx2 to CIC-2, or to an anti-GaTx2 antibody) can also be 
35 determined by physical analysis of structure, as determined 
by such techniques as nuclear magnetic resonance, crystal-
lography, electron diffraction or photoaffinity labeling, in 
conjunction with mutation of putative contact site amino 
acids. See, for example, de Vos et al., Science 255:306 (1992), 
40 Smithetal.,J. Mal. Biol. 224:899 (1992), and Wlodaveretal., 
FEES Lett. 309:59 (1992). 
Multiple amino acid substitutions can be made and tested 
using known methods of mutagenesis and screening, such as 
those disclosed by Reidhaar-Olson and Sauer (Science 241: 
45 53 (1988)) or Bowie and Sauer (Proc. Nat'! Acad. Sci. USA 
86:2152 (1989)). Briefly, these authors disclose methods for 
simultaneously randomizing two or more positions in a 
polypeptide, selecting for functional polypeptide, and then 
sequencing the mutagenized polypeptides to determine the 
50 spectrum of allowable substitutions at each position. Other 
methods that can be used include phage display (e.g., Low-
manetal.,Biochem. 30:10832 (1991), Ladner eta!., U.S. Pat. 
No. 5,223,409, Huse, international publication No. WO 
92/06204, and region-directed mutagenesis (Derbyshire et 
55 al., Gene 46:145 (1986), and Ner et al., DNA 7:127, (1988)). 
Moreover, GaTx2 labeled with biotin or FITC can be used for 
expression cloning ofGaTx2 ligands. 
Variants of nucleic acids encoding GaTx2 polypeptide 
(SEQ ID NO: 1) can also be generated through DNA shuffling 
60 as disclosed by Stemmer, Nature 370:389 (1994), Stemmer, 
Proc. Nat'! Acad. Sci. USA 91:10747 (1994), and interna-
tional publication No. WO 97/20078. Briefly, variant DNA 
molecules are generated by in vitro homologous recombina-
tion by random fragmentation of a parent DNA followed by 
65 reassembly using PCR, resulting in randomly introduced 
point mutations. This technique can be modified by using a 
family of parent DNA molecules, such as allelic variants or 
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DNA molecules from different species, to introduce addi-
tional variability into the process. Selection or screening for 
the desired activity, followed by additional iterations of 
mutagenesis and assay provides for rapid "evolution" of 
sequences by selecting for desirable mutations while simul- 5 
taneously selecting against detrimental changes. 
Mutagenesis methods as disclosed herein can be combined 
with high-throughput, automated screening methods to detect 
activity of cloned, mutagenized polypeptides in host cells. 
Mutagenized DNA molecules that encode biologically active 10 
polypeptides, or polypeptides that bind with anti-GaTx2 anti-
bodies, can be recovered from the host cells and rapidly 
sequenced using modern equipment. These methods allow 
the rapid determination of the importance ofindividual amino 15 
acid residues in a polypeptide of interest, and can be applied 
to polypeptides of unknown structure. 
4. Fragments of CIC Channel Ligands 
Another embodiment provides "functional fragments" of 
GaTx2 polypeptides and nucleic acid molecules encoding 20 
such functional fragments. Routine deletion analyses of 
nucleic acid molecules can be performed to obtain functional 
fragments of a nucleic acid molecule that encodes a GaTx2 
polypeptide. As an illustration, DNA molecules can be 
digested with Bal31 nuclease to obtain a series of nested 25 
deletions. The fragments are then inserted into expression 
vectors in proper reading frame, and the expressed polypep-
tides are isolated and tested forthe ability to bind anti-GaTx2 
antibodies. One alternative to exonuclease digestion is to use 
oligonucleotide-directed mutagenesis to introduce deletions 30 
or stop codons to specify production of a desired fragment. 
Alternatively, particular fragments of a GaTx2 gene can be 
synthesized using the polymerase chain reaction. 
This general approach is exemplified by studies on the 35 
truncation at either or both termini of interferons have been 
12 
tides can be identified using standard methods (see, for 
example, Geysen et al., Proc. Nat'! Acad. Sci. USA 81.3998 
(1983)). 
In contrast, polypeptide fragments or peptides may include 
an "antigenic epitope," which is a region of a protein molecule 
to which an antibody can specifically bind. Certain epitopes 
consist of a linear or contiguous stretch of amino acids, and 
the antigenicity of such an epitope is not disrupted by dena-
turing agents. It is known in the art that relatively short syn-
thetic peptides that can mimic epitopes of a protein can be 
used to stimulate the production of antibodies against the 
protein (see, for example, Sutcliffe et al., Science 219:660 
(1983)). Accordingly, antigenic epitope-bearing peptides and 
polypeptides of the present invention are useful to raise anti-
bodies that bind with the polypeptides described herein. 
Antigenic epitope-bearing peptides and polypeptides can 
contain at least four to ten amino acids, at least ten to fifteen 
amino acids, or about 15 to about 30 amino acids of an amino 
acid sequence disclosed herein. Such epitope-bearing pep-
tides and polypeptides can be produced by fragmenting a 
GaTx2 polypeptide, or by chemical peptide synthesis, as 
described herein. Moreover, epitopes can be selected by 
phage display ofrandom peptide libraries (see, for example, 
Lane and Stephen, Curr. Opin. Immunol. 5:268 (1993), and 
Cortese et al., Curr. Opin. Biotechnol. 7:616 (1996)). Stan-
dardmethods for identifying epitopes and producing antibod-
ies from small peptides that comprise an epitope are 
described, for example, by Mole, "Epitope Mapping," in 
Methods in Molecular Biology, Vol. 10, Manson (ed.), pages 
105-116 (The Humana Press, Inc. 1992), Price, "Production 
and Characterization of Synthetic Peptide-Derived Antibod-
ies," in Monoclonal Antibodies: Production, Engineering, 
and Clinical Application, Ritter and Ladyman (eds.), pages 
60-84 (Cambridge University Press 1995), and Coligan et al. 
(eds.), Current Protocols in Immunology, pages 9.3.1-9.3.5 
and pages 9.4.1-9.4.11 (John Wiley & Sons 1997). 
summarized by Horisberger and Di Marco, Pharmac. Ther. For any GaTx2 polypeptide, including variants and fusion 
66:507 (1995). Moreover, standard techniques for functional proteins, one ofordinary skill in the art can readily generate a 
analysis of proteins are described by, for example, Treuter et fully degenerate polynucleotide sequence encoding that vari-
al., Malec. Gen. Genet. 240:113 (1993), Content et al., 40 ant. Moreover, those or skill in the art can use standard soft-
"Expression and preliminary deletion analysis of the 42 kDa ware to devise GaTx2 variants based upon the nucleotide and 
2-5A synthetase induced by human interferon," in Biological amino acid sequences described herein. Accordingly, the 
Interferon Systems, Proceedings of ISIR-TNO Meeting on present invention includes a computer-readable medium 
Interferon Systems, Cantell (ed.), pages 65-72 (Nijhoff encoded with a data structure that provides at least one of the 
1987), Herschman, "The EGF Receptor," in Control of Ani- 45 following sequences: SEQ ID NO: 1. Suitable forms of com-
ma! Cell Proliferation, Vol. 1, Boynton et al., (eds.) pages puter-readable media include magnetic media and optically-
169-199 (Academic Press 1985), Coumailleau et al., J. Biol. readable media. Examples of magnetic media include a hard 
Chem. 270:29270 (1995); Fuknnaga et al., J. Biol. Chem. orfixeddrive,arandomaccessmemory(RAM)chip,afloppy 
270:25291 (1995); Yamaguchi et al., Biochem. Pharmacol. disk, digital linear tape (DLT), a disk cache, and a ZIP disk. 
50:1295 (1995), and Meisel et al., Plant Malec. Biol. 30:1 50 Optically readable media are exemplified by compact discs 
(1996). (e.g., CD-read only memory (ROM), CD-rewritable (RW), 
Another embodiment provides functional fragments of a and CD-recordable), and digital versatile/video discs (DVD) 
GaTx2 gene that have amino acid changes, compared with (e.g., DVD-ROM, DVD-RAM, and DVD+RW). 
SEQ ID NO: 1. A variant GaTx2 gene can be identified on the B. Peptidomimetics 
basis of structure by determining the level of identity with 55 Another embodiment provides peptidomimetics of the CIC 
disclosed nucleotide and amino acid sequences, as discussed channel ligands, for example SEQ ID NO: 1. Peptidomimet-
above. An alternative approach to identifying a variant gene ics, as used herein, refers to molecules bearing identifiable 
on the basis of structure is to determine whether a nucleic acid resemblance to the scorpion venom polypeptide, for example 
molecule encoding a potential variant GaTx2 gene can 
hybridize to a nucleic acid molecule comprising a nucleotide 60 
sequence. 
One embodiment provides polypeptide fragments or pep-
tides having an epitope-bearing portion of a GaTx2 polypep-
tide described herein. Such fragments or peptides may com-
prise an "immunogenic epitope," which is a part of a protein 65 
that elicits an antibody response when the entire protein is 
used as an immunogen. Immunogenic epitope-bearing pep-
SEQ ID NO: 1 that, as a ligand of a chloride channel, can 
imitate or inhibit the effect of the scorpion venom polypep-
tide. Exemplary CIC channel ligand peptidomimetics have 
increased bioavailability, biostability, bioefficiency, and/or 
bioselectivity against the biological target of the parent pep-
tide, for example CIC-2. 
Examples of peptidomimetics have been isolated as natural 
products, synthesized as libraries from novel subunits, and 
designed on the basis of X-ray crystallographic studies and 
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through an intricate knowledge of the biological mode of 
action of natural peptides. Examples of such peptidomimetic 
materials are described in Moore et al., Chem. Rev. 101(2), 
3893-4012 (2001). 
Peptidomimetics that structurally and/or functionally 
resemble a polypeptide embodiment may be made. Several 
approaches to make peptidomimetics that resemble polypep-
tides have been described (see, e.g., U.S. Pat. Nos. 5,288, 707; 
5,552,534; 5,811,515; 5,817,626; 5,817,879; 5,821,231; and 
14 
C. Vectors and Nucleic Acids Encoding CIC Channel 
Ligands 
Another embodiment provides nucleic acid compositions 
that may encode all or a biologically active part of GaTx2, e.g. 
the nucleic acids may encode all or part of SEQ ID NO: 1, and 
may be synthesized oligonucleotides, mRNA, cDNA, or 
genomic DNA. These polynucleotides can be used, when in a 
recombinant expression vector, to produce the encoded 
5,874,529). lO 
GaTx2 or functional fragment thereof. They are also useful as 
hybridization probes in methods of detecting scorpion venom 
toxins gene expression, specifically transcription. Accord-Peptidomimetic materials of the disclosed CIC channel 
ligands can be generated to fall within one of four categories 
of known peptidomimetics: a-peptides, ~-peptides, y-pep-
tides, and II-peptides. Copolymers of these peptides can also 15 
be used. 
ingly, one embodiment provides recombinant vectors and 
host cells containing a polynucleotide encoding GaTx2. 
Another embodiment provides polynucleotides coding for 
a scorpion venom toxin polypeptide sequence set forth in 
SEQ ID NO: 1 an identifying sequence thereof. An "identi-
fying sequence" is a contiguous sequence of residues at least 
about 10 nucleotides (nt) to about 20 nt in length, usually at 
Examples of a-peptide peptidomimetics include, but are 
not limited to, N,N'-linked oligoureas, oligopyrrolinones, 
oxazolidin-2-ones, azatides and azapeptides. 
Examples of ~-peptides include, but are not limited to, 
~-peptide foldamers, a-aminoxy acids, sulfur-containing 
~-peptide analogues, and hydrazino peptides. 
Examples of y-peptides include, but are not limited to, 
y-peptide foldamers, oligoureas, oligocarbamates, and phos-
phodiesters. 
Examples of II-peptides include, but are not limited to, 
alkene-based II-amino acids and carbopeptoids, such as pyra-
nose-based carbopeptoids and furanose-based carbopep-
toids. 
Other peptidomimetics of the CIC channel ligands can be 
oligomers having backbones which can adopt helical or sheet 
conformations. Example of such compounds include, but are 
not limited to, compounds having backbones utilizing bipy-
ridine segments, compounds having backbones utilizing sol-
vopho bic interactions, compounds having backbones utiliz-
ing side chain interactions, compounds having backbones 
utilizing hydrogen bonding interactions, and compounds 
having backbones utilizing metal coordination. 
20 least about 40 nt to about 55 nt in length, that uniquely 
identifies the provided sequence. Encompassed in the term 
"scorpion venom toxin-encoding polynucleotide" are poly-
nucleotides comprising about 10, 20, 25, 50, 72 contiguous 
25 
nucleotides coding for SEQ ID NO: 1. 
"Hybridization" refers to the association of two nucleic 
acid sequences to one another by hydrogen bonding. Two 
sequences will be placed in contact with one another under 
conditions that favor hydrogen bonding. Factors that affect 
this bonding include: the type and volume of solvent; reaction 
30 temperature; time of hybridization; agitation; agents to block 
the non-specific attachment of the liquid phase sequence to 
the solid support (Denhardt's reagent or BLOTTO); concen-
tration of the sequences; use of compounds to increase the 
35 rate of association of sequences ( dextran sulfate or polyeth-
ylene glycol); and the stringency of the washing conditions 
following hybridization. See Sambrook, et al., Molecular 
Cloning: A Laboratory Manual, 2nd Ed. (1989), Volume 2, 
Examples of compounds containing backbones utilizing 
bipyridine segments include, but are not limited to, oligo 40 
(pyridine-pyrimidines), oligo(pyridine-pyrimidines) with 
hydrazal linkers, and pyridine-pyridazines. 
chapter 9, pages 9.47 to 9.57. 
"Stringency" refers to conditions in a hybridization reac-
tion that favor association of very similar sequences over 
sequences that differ. For example, the combination of tem-
perature and salt concentration should be chosen that is 
approximately 120 to 200° C. below the calculated Tm of the 
Examples of compounds containing backbones utilizing 
solvophobic interactions include, but are not limited to, oli-
goguanidines, aedamers (structures which take advantage of 
the stacking properties of aromatic electron donor-acceptor 
interactions of covalently linked subunits) such as oligomers 
containing 1,4,5,8-naphthalene-tetracarboxylic diimide rings 
and 1,5-dialkoxynaphthalene rings, and cyclophanes such as 
substituted N-benzyl phenylpyridinium cyclophanes. 
Examples of compounds containing backbones utilizing 
side chain interactions include, but are not limited to, olig-
othiophenes such as olihothiophenes with chiral p-phenyl-
oxazoline side chains, and oligo(m-phenylene-ethynylene )s. 
Examples of compound containing backbones utilizing 
hydrogen bonding interactions include, but are not limited to, 
aromatic amide backbones such as oligo(acylated 2,2'-bipy-
ridine-3,3'-diamine )s and oligo(2,5-bis[2-aminophenyl] 
pyrazine)s, diaminopyridine backbones templated by cyanu-
rate, and phenylene-pyridine-pyrimidine ethynylene 
backbones templated by isophthalic acid. 
Examples of compounds containing backbones utilizing 
metal coordination include, but are not limited to, zinc bili-
nones, oligopyridines complexed with Co(II), Co(III), Cu(II), 
Ni(II), Pd(II), Cr(III), or Y(III), oligo(m-pheylene ethy-
nylene )s containing metal-coordinating cyano groups, and 
hexapyrrins. 
45 hybrid under study. The temperature and salt conditions can 
often be determined empirically in preliminary experiments 
in which samples of genomic DNA immobilized on filters are 
hybridized to the sequence of interest and then washed under 
conditions of different stringencies. See Sambrook, et al., 
50 supra, at page 9.50. 
Variables to consider when performing, for example, a 
Southern blot are (1) the complexity of the DNA being blotted 
and (2) the homology between the target and the sequences 
being detected. The total amount of the polynucleotides to be 
55 studied can vary a magnitude of 10, from 0.1 to 1 µg for a 
plasmid or phage digest to 10-9 to 10-3 µg for a single copy 
gene in a highly complex eukaryotic genome. For lower com-
plexity polynucleotides, substantially shorter blotting, 
hybridization, and exposure times, a smaller amount of start-
60 ing polynucleotides, and lower specific activity of a target 
polynucleotide can be used. For example, a single-copy yeast 
gene can be detected with an exposure time of only 1 hour 
starting with 1 µg of yeast DNA, blotting for two hours, and 
hybridizing for 48 hours with a target polynucleotide radio 
65 labeled with 108 cpm/µg. For a single-copy mammalian gene 
a conservative approach would start with 10 µg of DNA, blot 
overnight, and hybridize overnight in the presence of 10% 
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dextran sulfate using a target polynucleotide radiolabeled 
with greater than 108 cpm/µg, resulting in an exposure time of 
about 24 hours. 
Several factors can affect the melting temperature (Tm) of 
a DNA-DNA hybrid between the target and sequence ofinter-
est, and consequently, the appropriate conditions for hybrid-
ization and washing. In many cases the target is not 100% 
homologous to the fragment. Other commonly encountered 
variables include the length and total G+C content of the 
hybridizing sequences and the ionic strength and formamide 10 
content of the hybridization buffer. The effects of all of these 
factors can be approximated by a single equation. 
Tm=81+16.6(log 10 Ci)+0.4[% G+C)]-0.6(% forma-
mide)-600/n-0.5(% mismatch), where Ci is the salt concen-
tration (monovalent ions) and n is the length of the hybrid in 15 
base pairs (slightly modified from Meinkoth and Wahl, 
(1984) Anal. Biochem. 138:267 284). 
In designing a hybridization experiment, some factors 
affecting nucleic acid hybridization can be conveniently 
altered. The temperature of the hybridization and washes and 20 
the salt concentration during the washes are the simplest to 
adjust. As the temperature of the hybridization increases (i.e., 
stringency), it becomes less likely for hybridization to occur 
between strands that are nonhomologous, and as a result, 
background decreases. If the labeled probe is not completely 25 
homologous with the immobilized fragment (as is frequently 
the case in gene family and interspecies hybridization experi-
ments), the hybridization temperature must be reduced, and 
background will increase. The temperature of the washes 
affects the intensity of the hybridizing band and the degree of 30 
background in a similar manner. The stringency of the washes 
is also increased with decreasing salt concentrations. 
In general, convenient hybridization temperatures in the 
presence of 50% formamide are 42° C. for a target polynucle-
otide with 95% to 100% sequence identity to the sequence to 35 
be detected, 37° C. for 90% to 95% sequence identity, and 32° 
C. for 85% to 90% sequence identity. For lower percentage 
sequence identity, formamide content should be lowered and 
temperature adjusted accordingly, using the equation above. 
If the homology between the target polynucleotide and the 40 
sequence to be detected are not known, the simplest approach 
is to start with both hybridization and wash conditions which 
are nonstringent. If nonspecific bands or high background are 
observed after autoradiography, the filter can be washed at 
high stringency and reexposed. If the time required for expo- 45 
sure makes this approach impractical, several hybridization 
and/or washing stringencies should be tested in parallel. 
Stringent conditions include hybridization in a solution of at 
least about 5xSSC at 65° C., or at leastabout4xSSC at42° C.; 
see, for example, U.S. Pat. No. 5,707,829, the disclosure of 50 
which is herein incorporated by reference. 
Generally, hybridization is performed using at least 18 
contiguous nucleotides. That is, when at least 18 contiguous 
nucleotides are used as a probe, the probe will preferentially 
hybridize with a nucleic acid or mRNA comprising the 55 
complementary sequence, allowing the identification and 
retrieval of the nucleic acids of the biological material that 
uniquely hybridize to the selected probe. Probes of more than 
18 nucleotides can be used, e.g. probes of from about 25 
nucleotides to about 40 nucleotides, from about 50 nucle- 60 
otides to about 72 nucleotides, up to the entire coding region 
can be used, but 18 nucleotides generally represents sufficient 
sequence for unique identification. 
The nucleic acids may also include naturally occurring 
variants of the nucleotide sequences, e.g. degenerate variants, 65 
allelic variants, etc. Variants of the nucleic acids of the inven-
tion are identified by hybridization of putative variants with 
16 
nucleotide sequences disclosed herein preferably by hybrid-
ization under stringent conditions. For example, by using 
appropriate wash conditions, variants of the nucleic acids can 
be identified where the allelic variant exhibits at most about 
25-30% base pair mismatches relative to the selected nucleic 
acid probe. In general, allelic variants contain 15-25% base 
pair mismatches, and can contain as few as even 5-15%, or 
2-5%, or 1-2% base pair mismatches, as well as a single 
base-pair mismatch. 
Another embodiment provides homo logs of GaTx2. Such 
homo logs can be identified by any of a number of methods 
known to those skilled in the art. A fragment of the provided 
nucleic acid may be used as a hybridization probe against a 
cDNA library from the target organism of interest, where low 
stringency conditions are used. The probe may be a large 
fragment, or one or more short degenerate primers. 
The homo logs corresponding to the nucleic acids encoding 
SEQ ID NO: 1, where the source of homologous genes can be 
any related species within the same genus or group. Within a 
group, homologs have substantial sequence similarity, e.g. at 
least 75% sequence identity, usually at least 90%, more usu-
ally at least 95%, preferably 98% or greater between nucle-
otide sequences. Sequence similarity is calculated based on a 
reference sequence, which may be a subset of a larger 
sequence, such as a conserved motif, coding region, flanking 
region, etc. A reference sequence will usually be at least about 
18 contiguous nt long, more usually at least about 30 nt long, 
and may extend to the complete sequence that is being com-
pared. 
In some embodiments, the polynucleotide includes a 
nucleotide sequence encoding a polypeptide comprising at 
least about 5, 10, 15, 20, 25, 50, 75, 100, 125, or 150 amino 
acids of the sequence set forth in SEQ ID NO: 1. In other 
embodiments, the polynucleotide includes a nucleotide 
sequence encoding the entire polypeptide having the amino 
acid sequence set forth in any one of SEQ ID NO: 1. In still 
other embodiments, the polynucleotide includes a nucleotide 
sequence which encodes a polypeptide comprising an amino 
acid sequence sharing at least about 60%, preferably at least 
about 70%, more preferably at least about 80%, even more 
preferably at least about 87%, 90%, 95%, 96%, 97%, 98%, or 
99% or more amino acid sequence identity with the sequence 
depicted in SEQ ID NO: 1. 
As is known to one of skill in the art, using the standard 
genetic code table, a polynucleotide encoding a subject 
polypeptide can be designed and using a nucleic acid synthe-
sizer or other means, a polynucleotide encoding a subject 
polypeptide may be produced. 
Various derivatives of an antisense sequence specific for 
nucleic acids encoding GaTx2 may be prepared, where the 
phosphates may be modified, where oxygens may be substi-
tuted with sulfur and nitrogen, the sugars may be modified, 
and the like. The antisense sequences may be used by them-
selves or in conjunction with various toxic moieties, such as 
metal chelates, sensitizers, ribozymes, and the like. Antisense 
polynucleotides, and methods of using such, are described in 
numerous publications, including, e.g., "Antisense Technol-
ogy: A Practical Approach" Lichtenstein and Nellen, eds. 
(1997) IRL Press. 
Antisense molecules specific for GaTx2 can be used to 
down-regulate expression of GaTx2 in cells. The anti-sense 
reagent may be anti sense oligodeoxynucleotides (ODN), par-
ticularly synthetic ODN having chemical modifications from 
native nucleic acids, or nucleic acid constructs that express 
such anti-sense molecules as RNA. The anti sense sequence is 
complementary to the mRNA of the targeted gene, and inhib-
its expression of the targeted gene products. Antisense mo!-
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ecules inhibit gene expression through various mechanisms, 
e.g. by, reducing the amount of mRNA available for transla-
tion, through activation ofRNAse H, or steric hindrance. One 
or a combination of antisense molecules may be adminis-
tered, where a combination may comprise two or more dif-
ferent sequences. 
Antisense molecules may be produced by expression of all 
18 
region. The genomic DNA may be isolated as a fragment of 
50 kbp or smaller; and substantially free of flanking chromo-
somal sequence. The genomic DNA flanking the coding 
region, either 3' or 5', or internal regulatory sequences as 
sometimes found in intrans, contains sequences required for 
proper tissue and stage specific expression. 
The sequence of the 5' flanking region may be utilized for 
promoter elements, including enhancer binding sites, that 
provide for regulation in tissues where scorpion toxins 
10 polypeptide are expressed. The tissue specific expression is 
useful for determining the pattern of expression, and for pro-
viding promoters that mimic the native pattern of expression. 
Naturally occurring polymorphisms in the promoter region 
or a part of the target gene sequence in an appropriate vector, 
where the transcriptional initiation is oriented such that an 
antisense strand is produced as an RNA molecule. Alterna-
tively, the antisense molecule is a synthetic oligonucleotide. 
Anti sense oligonucleotides will generally be at least about 7, 
usually at least about 12, more usually at least about 20 
nucleotides in length, and not more than about 7 5, usually not 
more than about 50, more usually not more than about 35 15 
nucleotides in length, where the length is governed by effi-
ciency of inhibition, specificity, including absence of cross-
reactivity, and the like. It has been found that short oligo-
nucleotides, of from 7 to 8 bases in length, can be strong and 
selective inhibitors of gene expression (see Wagner et al. 
(1996) Nature Biotechnology 14:840 844). 
are useful for determining natural variations in expression. 
Alternatively, mutations may be introduced into the pro-
moter region to determine the effect of altering expression in 
experimentally defined systems. Methods for the identifica-
tion of specific DNA motifs involved in the binding of tran-
scriptional factors are known in the art, e.g. sequence simi-
20 larity to known binding motifs, gel retardation studies, etc. 
For examples, see Blackwell et al. (1995) Mal. Med. 1:194 
205; Mortlocket al. (1996) Genome Res. 6:327 33; andJoulin 
and Richard-Foy (1995) Eur. J. Biochem. 232:620 626. 
A specific region or regions of the endogenous sense strand 
mRNA sequence is chosen to be complemented by the anti-
sense sequence. Selection of a specific sequence for the oli-
gonucleotide may use an empirical method, where several 
candidate sequences are assayed for inhibition of expression 
of the target gene in an in vitro or animal model. A combina-
tion of sequences may also be used, where several regions of 
the mRNA sequence are selected for antisense complemen-
tation. 
Antisense oligonucleotides may be chemically synthe-
sized by methods known in the art (see Wagner et al. (1993) 
supra.) Preferred oligonucleotides are chemically modified 
from the native phosphodiester structure, in order to increase 
their intracellular stability and binding affinity. Such modifi-
cations have been previously discussed with respect to the use 
of probes. 
As an alternative to anti-sense inhibitors, catalytic nucleic 
acid compounds, e.g. ribozymes, anti-sense conjugates, 
siRNA, or micro RNA etc. may be used to inhibit gene expres-
sion. Ribozymes may be synthesized in vitro and adminis-
tered, or may be encoded on an expression vector, from which 
the ribozyme is synthesized in the targeted cell (for example, 
see International patent application WO 9523225, and 
Beigelman et al. (1995) Nucl. Acids Res. 23:4434 42). 
Examples of oligonucleotides with catalytic activity are 
described in WO 9506764. Conjugates of anti-sense ODN 
with a metal complex, e.g. terpyridylCu(II), capable of medi-
ating mRNA hydrolysis are described in Bashkin et al. (1995) 
Appl. Biochem. Biotechnol. 54:43 56. 
The regulatory sequences may be used to identify cis acting 
25 sequences required for transcriptional or translational regu-
lation of expression, especially in different tissues or stages of 
development, and to identify cis acting sequences and trans-
acting factors that regulate or mediate expression. Such tran-
scription or translational control regions may be operably 
30 linked to one of the subject genes in order to promote expres-
sion of wild type or altered scorpion toxin polypeptide, or 
other proteins of interest in cultured cells. 
The nucleic acid compositions may encode all or a part of 
GaTx2. Double or single stranded fragments of the DNA 
35 sequence may be obtained by chemically synthesizing oligo-
nucleotides in accordance with conventional methods, by 
restriction enzyme digestion, by PCR amplification, etc. For 
the most part, DNA fragments will be of at least 15 nt, usually 
at least 25 nt or 35 nt or 45 nt but may be as long as 50 nt, 60 
40 nt, 70 nt, 80 nt, and even as long as 90 nt or 100 nt. Small DNA 
fragments are useful as primers for PCR, hybridization 
screening probes, etc. For use in amplification reactions, such 
as PCR, a pair of primers will be used. The exact composition 
of the primer sequences is not critical to the invention, but for 
45 most applications the primers will hybridize to the subject 
sequence under stringent conditions, as known in the art. It is 
preferable to choose a pair of primers that will generate an 
amplification product of at least about 50 nt, preferably at 
least about 100 nt, Algorithms for the selection of primer 
50 sequences are generally known, and are available in commer-
cial software packages Amplification primers hybridize to 
complementary strands of DNA, and will prime towards each 
other. 
One embodiment provides an siRNA specific for mRNA 
encoding GaTx2. Still another embodiment provides a 
microRNA specific for mRNA encoding GaTx2. Still another 
embodiment provides a vector encoding a siRNA or 
microRNA specific for GaTx2 mRNA. One of ordinary skill 55 
in the art could readily identify siRNAs using commercially 
available software. 
The polynucleotides are isolated and obtained in substan-
tial purity, generally as other than an intact chromosome. 
Usually, the DNA will be obtained substantially free of 
nucleic acid sequences other than a scorpion venom toxin-
encoding polynucleotide, generally being at least about 50%, 
usually at least about 90% pure and are typically "recombi-
Another embodiment provides Ga Tx2 genomic sequences. 
60 nant", i.e. flanked by one or more nucleotides with which it is 
not normally associated on a naturally occurring chroma-
A genomic sequence of interest includes the nucleic acid 
present between the initiation codon and the stop codon, 
including all of the intrans that are normally present in a 
native chromosome. It may further include the 3' and 5' 
untranslated regions found in the mature mRNA. It may fur-
ther include specific transcriptional and translational regula-
tory sequences, such as promoters, enhancers, etc., including 65 
about 1 kb, but possibly more, up to about 6 kb, of flanking 
genomic DNA at either the 5' or 3' end of the transcribed 
some. 
The DNA may also be used to identify expression of the 
gene in a biological specimen. The marmer in which one 
probes cells for the presence of particular nucleotide 
sequences, as genomic DNA or RNA, is well established in 
the literature and does not require elaboration here. DNA or 
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mRNA is isolated from a cell sample. The mRNA may be 
amplified by RT-PCR, using reverse transcriptase to form a 
complementary DNA strand, followed by polymerase chain 
reaction amplification using primers specific for the subject 
DNA sequences. Alternatively, the mRNA sample is sepa-
rated by gel electrophoresis, transferred to a suitable support, 
e.g. nitrocellulose, nylon, etc., and then probed with a frag-
ment of the subject DNA as a probe. Other techniques, such as 
oligonucleotide ligation assays, in situ hybridizations, and 
hybridization to DNA probes arrayed on a solid chip may also 10 
find use. Detection of mRNA hybridizing to the subject 
sequence is indicative of scorpion toxin gene expression in 
the sample. 
The sequence of a GaTx2-encoding nucleic acid or gene, 
including any flanking promoter regions and coding regions, 15 
may be mutated in various ways known in the art to generate 
targeted changes in promoter strength, sequence of the 
encoded protein, etc. The DNA sequence or protein product 
of such a mutation will usually be substantially similar to the 
sequences provided herein, i.e. will differ by at least one 20 
amino acid, and may differ by at least one or two but not more 
than about ten amino acids. The sequence changes may be 
substitutions, insertions or deletions. Deletions may further 
include larger changes, such as deletions of a domain or exon. 
Other modifications of interest include epitope tagging, e.g. 25 
with the FLAG system, HA, etc. For studies of subcellular 
localization, fusion proteins with green fluorescent proteins 
(GFP) may be used. 
Techniques for in vitro mutagenesis of cloned genes are 
known. Examples of protocols for site specific mutagenesis 30 
may be found in Gustin et al., Biotechniques 14:22 (1993); 
Barany, Gene 37: 111 23 (1985); Colicelli et al, Mal. Gen. 
Genet. 199:537 9 (1985); and Prentki et al., Gene 29:303 13 
(1984). Methods for site specific mutagenesis can be found in 
Sambrook et al., Molecular Cloning: A Laboratory Manual, 35 
CSH Press 1989, pp. 15.3 15.108; Weiner et al., Gene 126:35 
41 (1993); Sayers etal.,Biotechniques 13:592 6 (1992); Jones 
and Winistorfer, Biotechniques 12:528 30 (1992); Barton et 
al., Nucleic Acids Res. 18:7349 55 (1990); Marotti and 
Tomich, Gene Anal. Tech. 6:67 70 (1989); and Zhu, Anal. 40 
Biochem. 177: 120 4 (1989). 
D. GaTx2 Homologs 
Homologs and orthologs of scorpion toxin polypeptides, 
for example GaTx2, are identified by any of a number of 
methods. A fragment of scorpion venom toxin polynucleotide 45 
or cDNA may be used as a hybridization probe against a 
cDNA library from the target organism of interest, where low 
stringency conditions are used. The probe may be a large 
fragment, or one or more short degenerate primers. Nucleic 
acids having sequence similarity are detected by hybridiza- 50 
tion under low stringency conditions, for example, at 50° C. 
and 6xSSC (0.9 M sodium chloride/0.09 M sodium citrate) 
and remain bound when subjected to washing at 55° C. in 
1xSSC (0.15 M sodium chloride/0.015 M sodium citrate). 
Sequence identity may be determined by hybridization under 55 
stringent conditions, for example, at 50° C. or higher and 
0.1xSSC (15 mM sodium chloride/01.5 mM sodium citrate). 
Hybridization methods and conditions are well known in the 
art, see, e.g., U.S. Pat. No. 5,707,829. Nucleic acids having a 
region of substantial identity to a nucleic acid encoding 60 
GaTx2, e.g. allelic variants, genetically altered versions of the 
gene, etc., bind to the GaTx2 sequence under stringent 
hybridization conditions. By using probes, particularly 
labeled probes of DNA sequences, one can isolate homolo-
gous or related genes. The source ofhomologous genes can be 65 
any species of scorpion or any other organism that produces 
neurotoxins, e.g., snakes, arachnids, lizards, sea anemones, 
20 
and the like. Between scorpion species, homologs have sub-
stantial sequence similarity, i.e. at least 75% sequence iden-
tity between nucleotide sequences, in some cases 80 or 90% 
sequence identity, and may be as high as 95%, 98%, or 99% 
sequence identity between closely related species. Sequence 
similarity is calculated based on a reference sequence, which 
may be a subset of a larger sequence, such as a conserved 
motif, coding region, flanking region, etc. A reference 
sequence will usually be at least about 18 nt long, more 
usually at least about 30 nt long, and may extend to the 
complete sequence that is being compared. Algorithms for 
sequence analysis are known in the art, such as BLAST, 
described inA!tschul et al. (1990) J. Mal. Biol. 215:403 10. 
E. Pharmaceutical Compositions 
Pharmaceutical compositions including a CIC channel 
ligand such as GaTx2 peptide are provided. Conditions alle-
viated or modulated by the administration of such composi-
tions include those indicated below. Such pharmaceutical 
compositions may be for administration by oral, parenteral 
(intramuscular, intraperitoneal, intravenous (IV) or subcuta-
neous injection), transdermal (either passively or using ion-
tophoresis or electroporation), transmucosal (nasal, vaginal, 
rectal, or sublingual) routes of administration or using bio-
erodible inserts and can be formulated in dosage forms appro-
priate for each route of administration. In general, pharma-
ceutical compositions are provided including effective 
amounts of a GaTx2 peptide, or derivative products, and 
pharmaceutically acceptable diluents, preservatives, solubi-
lizers, emulsifiers, adjuvants and/or carriers. Such composi-
tions include diluents of various buffer content (e.g., Tris-
HCI, acetate, phosphate), pH and ionic strength; additives 
such as detergents and solubilizing agents (e.g., TWEEN 20, 
TWEEN 80, Polysorbate 80), anti-oxidants (e.g., ascorbic 
acid, sodium meta bi sulfite), preservatives (e.g., Thimersol, 
benzyl alcohol) and bulking substances (e.g., lactose, manni-
tol); incorporation of the material into particulate prepara-
tions of polymeric compounds such as poly lactic acid, polyg-
lycolic acid, etc. or into liposomes. Hylauronic acid may also 
be used. Such compositions may influence the physical state, 
stability, rate of in vivo release, and rate of in vivo clearance 
of the present proteins and derivatives. See, e.g., Remington's 
Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing 
Co., Easton, Pa. 18042) pages 1435-1712 which are herein 
incorporated by reference. The compositions may be pre-
pared in liquid form, or may be in dried powder (e.g., lyo-
philized) form. 
1. Oral Delivery 
GaTx2 peptide can be formulated for oral delivery. Oral 
solid dosage forms are described generally in Remington's 
Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing 
Co. Easton Pa. 18042) at Chapter 89, which is herein incor-
porated by reference. Solid dosage forms include tablets, 
capsules, pills, troches or lozenges, cachets, pellets, powders, 
or granules. Also, Ii po soma! or proteinoid encapsulation may 
be used to formulate the present compositions (as, for 
example, proteinoid microspheres reported in U.S. Pat. No. 
4,925,673). Liposomal encapsulation may be used and the 
liposomes may be derivatized with various polymers (e.g., 
U.S. Pat. No. 5,013,556). A description of possible solid 
dosage forms for the therapeutic is given by Marshall, K. In: 
Modern Pharmaceutics Edited by 0, S. Banker and C. T. 
Rhodes Chapter 10, 1979, herein incorporated by reference. 
In general, the formulation will include the CIC channel 
ligands (or chemically modified forms thereof) and inert 
ingredients which allow for protection against the stomach 
environment, and release of the biologically active material in 
the intestine. 
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Another embodiment provides liquid dosage forms for oral 
administration, including pharmaceutically acceptable emul-
sions, solutions, suspensions, and syrups, which may contain 
other components including inert diluents; adjuvants such as 
wetting agents, emulsifying and suspending agents; and 
sweetening, flavoring, and perfuming agents. 
The peptides may be chemically modified so that oral 
delivery of the derivative is efficacious. Generally, the chemi-
cal modification contemplated is the attachment of at least 
one moiety to the component molecule itself where said moi-
ety permits (a) inhibition of proteolysis; and (b) uptake into 
the blood stream from the stomach or intestine. Also desired 
is the increase in overall stability of the component or com-
ponents and increase in circulation time in the body. As dis-
cussed above, PEGylation is a preferred chemical modifica-
tion for pharmaceutical usage. Other moieties that may be 
used include: propylene glycol, copolymers of ethylene gly-
col and propylene glycol, carboxymethyl cellulose, dextran, 
polyvinyl alcohol, polyvinyl pyrrolidone, polyproline, poly-
1,3-dioxolane and poly-1,3,6-tioxocane [see, e.g., Abu-
chowskli and Davis (1981) "Soluble Polymer-Enzyme 
Adducts," in Enzymes as Drugs. Hocenberg and Roberts, eds. 
(Wiley-Interscience. New York, N.Y.) pp. 367-383; and New-
mark, et al. (1982) J. Appl. Biochem. 4:185-189]. 
For oral formulations, the location of release may be the 
stomach, the small intestine (the duodenum, the jejunem, or 
the ileum), or the large intestine. One skilled in the art has 
available formulations which will not dissolve in the stomach, 
yet will release the material in the duodenum or elsewhere in 
the intestine. Preferably, the release will avoid the deleterious 
effects of the stomach environment, either by protection of 
the peptide (or derivative) or by release of the peptide (or 
derivative) beyond the stomach environment, such as in the 
intestine. 
To ensure full gastric resistance a coating impermeable to 
at least pH 5.0 is essential. Examples of the more common 
inert ingredients that are used as enteric coatings are cellulose 
acetate trimellitate (CAT), hydroxypropylmethylcellulose 
phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl 
acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellu-
lose acetate phthalate (CAP), Eudragit L, Eudragit S, and 
Shellac. These coatings may be used as mixed films. 
A coating or mixture of coatings can also be used on 
tablets, which are not intended for protection against the 
stomach. This can include sugar coatings, or coatings which 
make the tablet easier to swallow. Capsules may consist of a 
hard shell (such as gelatin) for delivery of dry therapeutic (i.e. 
powder), for liquid forms a soft gelatin shell may be used. The 
shell material of cachets could be thick starch or other edible 
paper. For pills, lozenges, molded tablets or tablet triturates, 
moist massing techniques can be used. 
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including calcium triphosphate, magnesium carbonate and 
sodium chloride. Some commercially available diluents are 
Fast-Flo, Emdex, STA-RX 1500, Emcompress andAvicell. 
Disintegrants may be included in the formulation of the 
therapeutic into a solid dosage form. Materials used as disin-
tegrants include but are not limited to starch, including the 
commercial disintegrant based on starch, Explotab. Sodium 
starch glycolate, Amberlite, sodium carboxymethylcellulose, 
ultramylopectin, sodium alginate, gelatin, orange peel, acid 
10 carboxymethyl cellulose, natural sponge and bentonite may 
all be used. The disintegrants may also be insoluble cationic 
exchange resins. Powdered gums may be used as disinte-
grants and as binders and can include powdered gums such as 
agar, Karaya or tragacanth. Alginic acid and its sodium salt 
15 are also useful as disintegrants. 
Binders may be used to hold the peptide (or derivative) 
agent together to form a hard tablet and include materials 
from natural products such as acacia, tragacanth, starch and 
gelatin. Others include methyl cellulose (MC), ethyl cellulose 
20 (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrroli-
done (PVP) and hydroxypropylmethyl cellulose (HPMC) 
could both be used in alcoholic solutions to granulate the 
peptide (or derivative). 
An antifrictional agent may be included in the formulation 
25 of the peptide (or derivative) to prevent sticking during the 
formulation process. Lubricants may be used as a layer 
between the peptide (or derivative) and the die wall, and these 
can include but are not limited to: stearic acid including its 
magnesium and calcium salts, polytetrafluoroethylene 
30 (PTFE), liquid paraffin, vegetable oils and waxes. Soluble 
lubricants may also be used such as sodium lauryl sulfate, 
magnesium lauryl sulfate, polyethylene glycol of various 
molecular weights, Carbowax 4000 and 6000. 
Glidants that might improve the flow properties of the drug 
35 during formulation and to aid rearrangement during compres-
sion might be added. The glidants may include starch, talc, 
pyrogenic silica and hydrated silicoaluminate. 
To aid dissolution of the peptide (or derivative) into the 
aqueous environment a surfactant might be added as a wetting 
40 agent. Surfactants may include anionic detergents such as 
sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dio-
ctyl sodium sulfonate. Cationic detergents might be used and 
could include benzalkonium chloride or benzethomium chlo-
ride. The list of potential nonionic detergents that could be 
45 included in the formulation as surfactants are lauromacrogol 
400, polyoxyl 40 stearate, polyoxyethylene hydrogenated 
castor oil 10, 50 and 60, glycerol monostearate, polysorbate 
20, 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellu-
lose and carboxymethyl cellulose. These surfactants could be 
50 present in the formulation of the protein or derivative either 
alone or as a mixture in different ratios. 
The peptide (or derivative) can be included in the formu-
lation as fine multiparticulates in the form of granules or 
pellets of particle size about 1 mm. The formulation of the 
material for capsule administration could also be as a powder, 55 
lightly compressed plugs, or even as tablets. These therapeu-
tics could be prepared by compression. 
Additives which potentially enhance uptake of the peptide 
(or derivative) are for instance the fatty acids oleic acid, 
linoleic acid and linolenic acid. 
Controlled release oral formulations may be desirable. The 
peptide (or derivative) could be incorporated into an inert 
matrix which permits release by either diffusion or leaching 
mechanisms, e.g., gums. Slowly degenerating matrices may 
also be incorporated into the formulation. Some enteric coat-
ings also have a delayed release effect. Another form of a 
controlled release is by a method based on the Oros therapeu-
Colorants and/or flavoring agents may also be included. 
For example, the peptide (or derivative) may be formulated 
(such as by liposome or microsphere encapsulation) and then 60 
further contained within an edible product, such as a refrig-
erated beverage containing colorants and flavoring agents. 
One may dilute or increase the volume of the peptide (or 
derivative) with an inert material. These diluents could 
include carbohydrates, especially mannitol, .alpha.-lactose, 65 
anhydrous lactose, cellulose, sucrose, modified dextrans and 
starch. Certain inorganic salts may be also be used as fillers 
tic system (Alza Corp.), i.e. the drug is enclosed in a semi-
permeable membrane which allows water to enter and push 
drug out through a single small opening due to osmotic 
effects. 
Other coatings may be used for the formulation. These 
include a variety of sugars which could be applied in a coating 
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pan. The peptide (or derivative) could also be given in a film 
coated tablet and the materials used in this instance are 
divided into 2 groups. The first are the nonenteric materials 
and include methyl cellulose, ethyl cellulose, hydroxyethyl 
cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl 
cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-
methyl cellulose, providone and the polyethylene glycols. 
The second group consists of the enteric materials that are 
commonly esters of phthalic acid. 
A mix of materials might be used to provide the optimum 
film coating. Film coating may be carried out in a pan coater 
or in a fluidized bed or by compression coating. 
2. Parenteral Delivery 
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may involve the use of an appropriate propellant material, in 
addition to the usual diluents, adjuvants and/or carriers useful 
in therapy. Also, the use of liposomes, microcapsules or 
microspheres, inclusion complexes, or other types of carriers 
is contemplated. Chemically modified peptides may also be 
prepared in different formulations depending on the type of 
chemical modification or the type of device employed. 
Formulations suitable for use with a nebulizer, either jet or 
ultrasonic, will typically comprise peptide (or derivative) dis-
lO solved in water at a concentration of about 0.1 to 25 mg of 
biologically active protein per mL of solution. The formula-
tion may also include a buffer and a simple sugar (e.g., for 
protein stabilization and regulation of osmotic pressure). The Preparations according to this invention for parenteral 
administration include sterile aqueous or non-aqueous solu-
tions, suspensions, or emulsions. Examples of non-aqueous 
solvents or vehicles are propylene glycol, polyethylene gly-
col, vegetable oils, such as olive oil and corn oil, gelatin, and 
injectable organic esters such as ethyl oleate. Such dosage 
forms may also contain adjuvants such as preserving, wetting, 20 
emulsifying, and dispersing agents. They may be sterilized 
by, for example, filtration through a bacteria retaining filter, 
15 nebulizer formulation may also contain a surfactant, to reduce 
or prevent surface induced aggregation of the peptide (or 
derivative) caused by atomization of the solution in forming 
the aerosol. 
Formulations for use with a metered-dose inhaler device 
will generally include a finely divided powder containing the 
peptide (or derivative) suspended in a propellant with the aid 
of a surfactant. The propellant may be any conventional mate-
rial employed for this purpose, such as a chlorofluorocarbon, 
a hydrochlorofluorocarbon, a hydro fluorocarbon, or a hydro-
by incorporating sterilizing agents into the compositions, by 
irradiating the compositions, or by heating the compositions. 
They can also be manufactured using sterile water, or some 25 
other sterile injectable medium, immediately before use. 
carbon, including trichlorofluoromethane, dichlorodifluo-
romethane, dichlorotetrafluoroethanol, and 1, 1, 1,2-tetrafluo-
3. Rectal or Vaginal Delivery 
Compositions for rectal or vaginal administration are pref-
erably suppositories which may contain, in addition to the 
active substance, excipients such as cocoa butter or a supposi- 30 
tory wax. Compositions for nasal or sublingual administra-
tion are also prepared with standard excipients well known in 
the art. 
roethane, or combinations thereof, Suitable surfactants 
include sorbitan trioleate and soya lecithin. Oleic acid may 
also be useful as a surfactant. 
Formulations for dispensing from a powder inhaler device 
will include a finely divided dry powder containing peptide 
(or derivative) and may also include a bulking agent, such as 
lactose, sorbitol, sucrose, or mannitol in amounts which 4. Pulmonary Delivery 
Also contemplated herein is pulmonary delivery of the 
GaTx2 peptides (or derivatives thereof). The peptide (or 
derivative) is delivered to the lungs of a marmnal while inhal-
ing and traverses across the lung epithelial lining to the blood 
stream [see, e.g., Adjei, et al. (1990) Pharmaceutical 
Research 7:565-569; Adjei, et al. (1990) Int. J. Pharmaceu-
tics 63:135-144 (leuprolide acetate); Braquet, et al. (1989) J. 
Cardiovascular Pharmacology 13(sup5):143-146 (endothe-
lin-1); Hubbard, et al. (1989) Annals of Internal Medicine, 
Vol. III, pp. 206-212 (al-antitrypsin); Smith, et al. (1989) J. 
Clin. Invest 84:1145-1146 (.alpha.-1-proteinase); Oswein, et 
al. (1990) "Aerosolization of Proteins", Proceedings of Sym-
posium on Respiratory Drug Delivery II Keystone, Colorado 
(recombinant human growth hormone); Debs, et al. (1988) J. 
Immunol 140:3482-3488 (interferon-.gamma. and tumor 
necrosis factor .alpha.); and U.S. Pat. No. 5,284,656 to Platz, 
et al. (granulocyte colony stimulating factor). A method and 
composition for pulmonary delivery of drugs for systemic 
effect is described in U.S. Pat. No. 5,451,569 to Wong, et al. 
A wide range of mechanical devices designed for pulmo-
nary delivery of therapeutic products can be used, including 
but not limited to nebulizers, metered dose inhalers, and pow-
der inhalers, all of which are familiar to those skilled in the art. 
Some specific examples of commercially available devices 
suitable for the practice of this invention are the Ultravent 
nebulizer (Mallinckrodt Inc., St. Louis, Mo.); the Acorn II 
nebulizer (Marquest Medical Products, Englewood, Colo.); 
the Ventolin metered dose inhaler (Glaxo Inc, Research Tri-
angle Park, N.C.); and the Spinhaler powder inhaler (Fisons 
Corp., Bedford, Mass.). 
All such devices require the use of formulations suitable 
for the dispensing of peptide (or derivative). Typically, each 
formulation is specific to the type of device employed and 
35 facilitate dispersal of the powder from the device, e.g., 50 to 
90% by weight of the formulation. The peptide (or derivative) 
should most advantageously be prepared in particulate form 
with an average particle size ofless than 10 mm (or microns), 
most preferably 0.5 to 5 mm, for most effective delivery to the 
40 distal lung. 
5. Nasal Delivery 
Nasal delivery of the CIC charmel ligand (or derivatives) is 
also contemplated. Nasal delivery allows the passage of the 
peptide to the blood stream directly after administering the 
45 therapeutic product to the nose, without the necessity for 
deposition of the product in the lung. Formulations for nasal 
delivery include those with dextran or cyclodextran. 
Other penetration-enhancers used to facilitate nasal deliv-
ery are also contemplated for use with the peptides of the 
50 present invention (such as described in International Patent 
Publication No. WO 2004056314, filed Dec. 17, 2003, incor-
porated herein by reference in its entirety). 
6. Dosages 
For all of the peptide compounds, as further studies are 
55 conducted, information will emerge regarding appropriate 
dosage levels for treatment of various conditions in various 
patients, and the ordinary skilled worker, considering the 
therapeutic context, age, and general health of the recipient, 
will be able to ascertain proper dosing. The selected dosage 
60 depends upon the desired therapeutic effect, on the route of 
administration, and on the duration of the treatment desired. 
Generally dosage levels of0.001 to 10 mg/kg of body weight 
daily are administered to mammals. Generally, for intrave-
nous injection or infusion, dosage may be lower. The phar-
65 maceutical compositions are formulated to contain an amount 
of GaTx2 effective to inhibit CIC channels when adminis-
tered to a host in need thereof. 
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7. Polymeric Matrices 
Both non-biodegradable and biodegradable matrices can 
be used for delivery of CIC channel ligands such as GaTx2 
peptides, although biodegradable matrices are preferred. 
These may be natural or synthetic polymers, although syn- 5 
thetic polymers are preferred due to the better characteriza-
tion of degradation and release profiles. The polymer is 
selected based on the period over which release is desired. In 
some cases linear release may be most useful, although in 
others a pulse release or "bulk release" may provide more 10 
effective results. The polymer may be in the form of a hydro-
gel (typically in absorbing up to about 90% by weight of 
water), and can optionally be crosslinked with multivalent 
ions or polymers. 
Representative synthetic polymers that cal be used for 15 
delivery include polyamides, polycarbonates, polyalkylenes, 
polyallylene glycols, polyalkylene oxides, polyalkylene 
terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl 
esters, polyvinyl halides, polyvinylpyrrolidone, polygly-
colides, polysiloxanes, polyurethanes and co-polymers 20 
thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose 
ethers, cellulose esters, nitro celluloses, polymers of acrylic 
and methacrylic esters, methyl cellulose, ethyl cellulose, 
hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, 
hydroxybutyl methyl cellulose, cellulose acetate, cellulose 25 
propionate, cellulose acetate butyrate, cellulose acetate 
phthalate, carboxylethyl cellulose, cellulose triacetate, cellu-
lose sulphate sodium salt, poly(methyl methacrylate), poly 
(ethyl methacrylate ), poly(butylmethacrylate ), poly(isobutyl 
methacrylate ), poly(hexylmethacrylate ), poly(isodecyl 30 
methacrylate ), poly(lauryl methacrylate ), poly(phenyl meth-
acrylate ), poly( methyl acrylate), poly(isopropyl acrylate), 
poly(isobutyl acrylate), poly( octadecyl acrylate), polyethyl-
ene, polypropylene, poly( ethylene glycol), poly( ethylene 
oxide), poly( ethylene terephthalate ), poly( vinyl alcohols), 35 
poly( vinyl acetate, poly vinyl chloride, polystyrene and poly-
vinylpyrrolidone. 
Examples of non-biodegradable polymers include ethyl-
ene vinyl acetate, poly(meth)acrylic acid, polyamides, 
copolymers and mixtures thereof. Examples of biodegrad- 40 
able polymers include synthetic polymers such as polymers 
of lactic acid and glycolic acid, polyanhydrides, poly( ortho) 
esters, polyurethanes, poly(butic acid), poly(valeric acid), 
and poly(lactide-co-caprolactone ), and natural polymers 
such as alginate and other polysaccharides including dextran 45 
and cellulose, collagen, chemical derivatives thereof (substi-
tutions, additions of chemical groups, for example, alkyl, 
alkylene, hydroxylations, oxidations, and other modifications 
routinely made by those skilled in the art), albumin and other 
hydrophilic proteins, zein and other prolamines and hydro- 50 
phobic proteins, copolymers and mixtures thereof, In general, 
these materials degrade either by enzymatic hydrolysis or 
exposure to water in vivo, by surface or bulk erosion. 
Bioadhesive polymers of particular interest include bio-
erodible hydrogels described by H. S. Sawhney, C. P. Pathak 55 
and J. A. Hubell in Macromolecules, 1993, 26, 581-587, 
polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, 
polyacrylic acid, alginate, chitosan, poly(methyl methacry-
lates ), poly( ethylmethacrylates), poly(butylmethaerylate ), 
poly(isobutyl methacrylate ), poly(hexylmethacrylate ), poly 60 
(isodecyl methacrylate ), poly(lauryl methacrylate ), poly 
(phenyl methacrylate ), poly( methyl acrylate), poly(isopropyl 
acrylate), poly(isobutyl acrylate), and poly( octadecyl acry-
late). 
The matrix can be in the form of microparticles such as 65 
microspheres, where peptides are dispersed within a solid 
polymeric matrix or microcapsules, where the core is of a 
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different material than the polymeric shell, and the peptide is 
dispersed or suspended in the core, which may be liquid or 
solid in nature. Unless specifically defined herein, micropar-
ticles, microspheres, and microcapsules are used inter-
changeably. Alternatively, the polymer may be cast as a thin 
slab or film, ranging from nanometers to four centimeters, a 
powder produced by grinding or other standard techniques, or 
even a gel such as a hydrogel. 
The matrices can be formed by solvent evaporation, spray 
drying, solvent extraction and other methods known to those 
skilled in the art. 
Bioerodible microspheres can be prepared using any of the 
methods developed for making microspheres for drug deliv-
ery, for example, as described by Mathiowitz and Langer, J. 
Controlled Release 5, 13-22 (1987); Mathiowitz, et al., Reac-
tive Polymers 6, 275-283 (1987); and Mathiowitz, et al., J. 
Appl. Polymer Sci. 35, 755-774 (1988). The selection of the 
method depends on the polymer selection, the size, external 
morphology, and crystallinity that is desired, as described, for 
example, by Mathiowitz, et al., Scanning Microscopy 4,329-
340 (1990); Mathiowitz, et al., J. Appl. Polymer Sci. 45, 
125-134 (1992); and Benita, et al., J. Pharm. Sci. 73, 1721-
1724 (1984 ). In solvent evaporation, described for example, 
in Mathiowitz, et al., (1990), Benita, and U.S. Pat. No. 4,272, 
398 to Jaffe, the polymer is dissolved in a volatile organic 
solvent. The peptide either in soluble form or dispersed as fine 
particles, is added to the polymer solution, and the mixture is 
suspended in an aqueous phase that contains a surface active 
agent such as poly(vinyl alcohol). The resulting emulsion is 
stirred until most of the organic solvent evaporates, leaving 
solid microspheres. In general, the polymer can be dissolved 
in methylene chloride. Microspheres with different sizes 
(1-1000 microns) and morphologies can be obtained by this 
method which is useful for relatively stable polymers such as 
polyesters and polystyrene. However, labile polymers such as 
polyanhydrides may degrade due to exposure to water. For 
these polymers, hot melt encapsulation and solvent removal 
may be preferred. 
In hot melt encapsulation, the polymer is first melted and 
then mixed with the solid particles of peptides. The mixture is 
suspended in a non-miscible solvent such as silicon oil and, 
with continuous stirring, heated to 5° C. above the melting 
point of the polymer. Once the emulsion is stabilized, it is 
cooled until the polymer particles solidify. The resulting 
microspheres are washed by decantation with petroleum 
ether to give a free-flowing powder. Microspheres with diam-
eters between one and 1000 microns can be obtained with this 
method. The external surface of spheres prepared with this 
technique is usually smooth and dense. This procedure is 
useful with water labile polymers, but is limited to use with 
polymers with molecular weights between 1000 and 50000. 
Solvent removal was primarily designed for use with polyan-
hydrides. In this method, the drug is dispersed or dissolved in 
a solution of a selected polymer in a volatile organic solvent 
like methylene chloride. The mixture is then suspended in oil, 
such as silicon oil, by stirring, to form an emulsion. Within 24 
hours, the solvent diffuses into the oil phase and the emulsion 
droplets harden into solid polymer microspheres. Unlike sol-
vent evaporation, this method can be used to make micro-
spheres from polymers with high melting points and a wide 
range of molecular weights. Microspheres having a diameter 
between one and 300 microns can be obtained with this pro-
cedure. The external morphology of the spheres is highly 
dependent on the type of polymer used. In spray drying, the 
polymer is dissolved in methylene chloride (0.04 g/ml). A 
known amount of active drug is suspended (if insoluble) or 
co-dissolved (if soluble) in the polymer solution. The solution 
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or the dispersion is then spray-dried. Double walled micro-
spheres can be prepared according to U.S. Pat. No. 4,861,627 
to Mathiowitz. 
Hydro gel micro spheres made of gel-type polymers such as 
alginate or polyphosphazines or other dicarboxylic polymers 
can be prepared by dissolving the polymer in an aqueous 
solution, suspending the material to be incorporated into the 
mixture, and extruding the polymer mixture through a micro-
droplet forming device, equipped with a nitrogen gas jet. The 
resulting microspheres fall into a slowly stirring, ionic hard- 10 
erring bath, as described, for example, by Salib, et al., Phar-
mazeutische Industrie 40-1 lA, 1230 (1978). Chitosan micro-
spheres can be prepared by dissolving the polymer in acidic 
solution and crosslinking with tripolyphosphate. For 
example, carboxymethylcellulose (CMC) microsphere are 15 
prepared by dissolving the polymer in an acid solution and 
precipitating the microspheres with lead ions. Alginate/poly-
ethylene imide (PEI) can be prepared to reduce the amount of 
carboxyl groups on the alginate microcapsules. 
Other delivery systems including films, coatings, pellets, 20 
slabs, and devices can be fabricated using solvent or melt 
casting, and extrusion, as well as standard methods for mak-
ing composites. The polymer can be produced by first mixing 
monomers and peptides as described by Sawhney, et al., and 
polymerizing the monomers with UV light. The polymeriza- 25 
tion can be carried out in vitro as well as in vivo. 
F. Fusion Proteins 
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The CIC channel ligand can be operably linked to an anti-
body or antigen-binding fragment of the antibody so that the 
CIC channel ligand can be selectively delivered to a target 
expressing an epitope recognized by the antibody. The anti-
body can be a single chain antibody, monoclonal antibody, 
polyclonal antibody, humanized antibody, or chimeric anti-
body. 
III. Methods of Manufacture 
A. Purification 
A bioassay-guided fractionation of Lqh venom may be 
used to isolate a peptide ligand that interacts with CIC chan-
nels, for example CIC-2. The fractionation approach may 
include, for example, the following steps: homogenization to 
disrupt mucus contained in the venom, recovery of compo-
nents below 10 kDa molecular weight by separation through 
a centrifuge filter resulting in "Lqh-pf venom", testing for 
activity against the ion channel expressed in Xenopus 
oocytes, using recordings from inside-out or outside-out 
single-channel patches or macropatches, fractionation 
according to hydrophobicity by reversed-phase HPLC(RP-
HPLC) in a gradient of acetonitrile in water, testing fractions 
for activity against CIC-2 expressed in Xenopus oocytes, 
using recordings from inside-out or outside-out single-chan-
nel patches or macropatches or TEVC, desalting of fractions 
using RP-HPLC, with collection of individual chromato-
graphic peaks, testing for activity against the ion channel 
expressed inXenopus oocytes, using recordings from single-
channel patches and/or macropatches, characterization of 
material represented in individual chromatographic peak 
30 using MALDI-TOF, and breaking of the disulfide bridges in 
the isolated toxin by reduction and subsequent carboxami-
domethylation of free cysteines. The primary sequence may 
be determined using Edman degradation, but any known 
Another embodiment provides a fusion protein including 
GaTx2 or a biologically active fragment thereof is fused to a 
heterologous peptide or protein. A fusion protein is a protein 
created through genetic engineering from two or more pro-
teins/peptides. This is achieved by creating a fusion gene: 
removing the stop codon from the DNA sequence of the first 
protein, then appending the DNA sequence of the second 
protein in frame. That DNA sequence will then be expressed 35 
by a cell as a single protein. 
In one embodiment a linker (or "spacer") peptides are also 
added which make it more likely that the proteins fold inde-
pendently and behave as expected. Especially in the case 
where the linkers enable protein purification, linkers in pro-
tein or peptide fusions can be engineered with cleavage sites 
for proteases or chemical agents which enable the liberation 
of the two separate proteins. 
The disclosed fusion proteins are useful for identification 
and purification of GaTx2, by fusing a GST protein, FLAG 
peptide, or a hexa-his peptide (a 6xhis-tag) which can be 
isolated using nickel or cobalt resins (affinity chromatogra-
phy). 
In one embodiment GaTx2 or derivative thereof can be 
fused to a cytotoxic moiety such as ricin, saporin, or pseud-
onomas exotoxin. Such fusion proteins can be useful for 
delivering cytotoxic materials to cells with chloride channels. 
In another embodiment, GaTx2 peptide can be labeled with 
a radioisotope, for example I 125 , fluorophore, or other detect-
able agent. Labeled GaTx2 can be useful for detecting chlo-
ride channels in a biological sample, in particular for detect-
ing CIC-2, or for the selective ablation of cells over-producing 
CIC-2. 
method of amino acid sequences may be used. 
B. Synthesis of CIC Channel Ligands 
Certain embodiments provide peptides that selectively 
bind to CIC channels including anion channels and inhibit the 
transport anions through the channel. These peptide ligands 
of anion channels can be synthesized using general methods 
40 for peptide synthesis and purification, and disulfide bond 
formation, known in the art. As described in the Examples, 
linear peptides were produced by solid phase synthesis using 
9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Coupling of 
Fmoc amino acids was performed using the HBTU/HOBT/ 
45 DIPEA method on an Applied Biosystems 43 lA synthesizer. 
The purified linear peptide was subjected to oxidative 
cyclization under equilibrating conditions in order to promote 
formation of the most stable disulfide bridges, with the reac-
tion being monitored by analytical HPLC. Cyclized peptide 
50 was isolated from the acidified reaction mixture by reversed 
phase extraction, was purified by HPLC, and was character-
ized by MALDI-MS for molecular weight determination and 
by analytical HPLC for comparison with the native toxin. 
Another embodiment provides polypeptides having 97%, 
55 98% or 99% sequence identity or greater to SEQ ID NO: 1, 
preferably having 99% sequence identity or greater to SEQ 
ID NO: 1 optionally where one or more amino acids are 
modified, such as by incorporation of biotin, or are substi-
Still another embodiment provides an CIC channel ligand 
fused to protein transduction domain, localization signal or 60 
both. Protein transduction domains include but are not limited 
tuted by non-natural amino acids. 
Synthetic peptides representing portions of the instant 
amino acid sequences may be synthesized by solid-phase 
chemistry. Alternatively, toxin peptides may be produced by 
recombinant methods upon expression in prokaryotic or 
eukaryotic cells, These peptides can be used to immunize 
to HIV TAT YGRKKRRQRRR (SEQ. ID NO. 2) or 
RKKRRQRRR (SEQ. ID NO. 3); 11 Arginine residues, or 
positively charged polypeptides or polynucleotides having 
8-15 residues, preferably 9-11 residues, Antp SGRQIKIW-
FQN-RRMKWKKC (SEQ ID N0:4), and HIV Tat 
SGYGRKKRRQRRRC (SEQ ID N0:5). 
65 animals to produce polyclonal or monoclonal antibodies with 
specificity for peptides or proteins comprising the amino acid 
sequences. These antibodies can be then be used to screen 
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cDNA expression libraries to isolate full-length cDNA clones 
of interest (Lerner (1984) Adv. Immunol. 36: 1-34; Maniatis). 
IV. Methods of Using CIC Channel Ligands 
A. Methods of Treatment 
Diseases, disorders, or symptoms of disease or disorders 
related to aberrant CIC channel activity can be treated using 
the disclosed CIC channel ligands. For example, diseases 
associated with defective or overactive ion channels, in par-
ticular chloride channels, can be treated using the disclosed 
peptides and peptide compositions. One embodiment pro-
vides a method of treating a subject by administering to the 
subject an effective amount of the pharmaceutical composi-
tion including a therapeutically effective amount of a CIC 
channel ligand, for example GaTx2, a variant or a pharma-
ceutically acceptable salt or solvate thereof. By "pharmaceu-
tically acceptable salts" is meant any salts that are known or 
later discovered to be pharmaceutically acceptable. Some 
examples are: acetate; trifluoroacetate; hydrohalides, such as 
hydrochloride and hydrobromide; sulfate; citrate; maleate; 
tartrate; glycolate; gluconate; succinate; mesylate; besylate; 
and oxalate salts. Some diseases attributed to defective, aber-
rant or overactive ion channels, in particular overactive chlo-
ride ion channels include cancer, cystic fibrosis, epilepsy, 
renal tubular disorders, Bartter's syndrome, Dent's disease, 
myotonia, osteopetrosis, Angleman or Prader-Willi, upregu-
lation of chloride channels in glioma cells, diarrhea-predomi-
nant inflammatory bowel syndrome, secretory diarrhea, exci-
totoxic neuronal injury, and in autosomal dominant 
polycystic kidney disease (ADPKD). 
Another embodiment provides a method of treating a dis-
order or a symptom of disorder selected from the group con-
sisting of cancer, cystic fibrosis, epilepsy, renal tubular dis-
orders, Bartter's syndrome, Dent's disease, myotonia, 
osteopetrosis, Angleman or Prader-Willi, upregulation of 
chloride channels in glioma cells, diarrhea-predominant 
inflammatory bowel syndrome, autosomal dominant poly-
cystic kidney disease (ADPKD), excitotoxic neuronal injury, 
and secretory diarrhea, as well as other disorders, by admin-
istering to a host in need thereof an effective amount of 
GaTx2, a variant, derivative, or a prodrug thereof. 
Yet another embodiment provides a method for reducing 
CIC channel activity by contacting the CIC channel with a 
ligand having at least 97% sequence identity to SEQ ID NO: 
1. 
Another embodiment provides a method for reducing chlo-
ride channel function by contacting the chloride channel with 
a GaTx2 peptide, variant, derivative or prodrug thereof. 
Still another embodiment provides a method for treating a 
disorder or symptom of a disorder related to an overactive 
chloride channel including administering a pharmaceutical 
composition including an effective amount of GaTx2, a 
derivative, variant or prodrug thereof. 
Another embodiment provides a method for reducing chlo-
ride ion transport through CIC-2 by contacting CIC-2 with a 
peptide ligand or biologically active fragment thereofisolated 
from scorpion venom. The scorpion venom peptide ligand 
can be GaTx2 or a biologically active fragment thereof. 
Another embodiment provides a method of inhibiting an 
CIC channel or a domain thereof by contacting the CIC chan-
nel with GaTx2, a variant thereof, a derivative thereof, or a 
biologically active fragment thereof. 
In one embodiment the GaTx2 is a ligand for one or more 
CIC channels. 
B. Detection Methods 
30 
useful for identifying agents which affect CIC channel ligand 
activity (e.g., ion channel binding) and/or CIC channel ligand 
mRNA and/or polypeptide levels. Detection methods include 
methods for detecting CIC channel ligands in a biological 
sample, methods for detecting CIC channel ligand mRNA in 
a biological sample, and methods for detecting CIC channel 
ligand-ion channel binding in a biological sample. 
1. Methods of Detecting GaTx2 in a Biological Sample 
Other embodiments provide methods for detecting the 
10 presence and/or measuring a level of an CIC channel ligand, 
for example GaTx2, in a biological sample, using a CIC 
channel ligand-specific antibody. The methods generally 
include: 
a) contacting the sample with an antibody specific for 
15 GaTx2; and 
b) detecting binding between the antibody and molecules 
of the sample. 
Detection of specific binding of the GaTx2-specific anti-
body, when compared to a suitable control, is an indication 
20 that CIC channel ligands are present in the sample. Suitable 
controls include a sample known not to contain a CIC channel 
ligand (GaTx2); and a sample contacted with an antibody not 
specific for a CIC channel ligand, e.g., an anti-idiotype anti-
body. A variety of methods to detect specific antibody-anti-
25 gen interactions are known in the art and can be used in the 
method, including, but not limited to, standard immunohis-
tological methods, immunoprecipitation, an enzyme immu-
noassay, and a radioimmunoassay. In general, the scorpion 
venom toxin polypeptide-specific antibody will be delectably 
30 labeled, either directly or indirectly. Direct labels include 
radioisotopes; enzymes whose products are detectable (e.g., 
luciferase, ~-galactosidase, and the like); fluorescent labels 
(e.g., fluorescein isothiocyanate, rhodamine, phycoerythrin, 
and the like); fluorescence emitting metals, e.g., 152Eu, or 
35 others of the lanthanide series, attached to the antibody 
through metal chelating groups such as EDTA; chemilumi-
nescent compounds, e.g., luminol, isoluminol, acridinium 
salts, and the like; bioluminescent compounds, e.g., luciferin, 
aequorin (green fluorescent protein), and the like. The anti-
40 body may be attached (coupled) to an insoluble support, such 
as a polystyrene plate or a bead. Indirect labels include second 
antibodies specific for scorpion venom toxin polypeptide-
specific antibodies, wherein the second antibody is labeled as 
described above; and members of specific binding pairs, e.g., 
45 biotin-avidin, and the like. The biological sample may be 
brought into contact with and immobilized on a solid support 
or carrier, such as nitrocellulose, that is capable of immobi-
lizing cells, cell particles, or soluble proteins. The support 
may then be washed with suitable buffers, followed by con-
50 tacting with a detectably-labeled scorpion venom toxin 
polypeptide-specific antibody. Detection methods are known 
in the art and will be chosen as appropriate to the signal 
emitted by the detectable label. Detection is generally accom-
plished in comparison to suitable controls, and to appropriate 
55 standards. 
Still other embodiments provide methods for detecting the 
presence and/or measuring a level of GaTx2 in a biological 
sample. The methods generally comprise: 
a) contacting the sample with an CIC channel, for example 
60 CIC-2 protein or fragment thereof, and 
b) detecting binding between the CIC channel and mol-
ecules of the sample. 
Detection of specific binding of the CIC channel is an indi-
cation that GaTx2 polypeptides are present in the sample. 
Various embodiments provide a variety of detection meth- 65 
ods, which methods are useful in diagnostic assays. Also 
provided are a variety of screening assays, which assays are 
Methods for detecting binding between a CIC channel 
ligand and an CIC channel are known in the art and include 
immunoprecipitation of CIC channel-ligand complexes using 
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6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-car-
boxyfluorescein (5-FAM) or N,N,N=,N-tetramethyl-6-car-
boxyrhodamine (TAMRA), radioactive labels, e.g. 32P, 35 S, 
3H; etc. The label may be a two stage system, where the 
amplified DNA is conjugated to biotin, haptens, etc. having a 
high affinity binding partner, e.g. avidin, specific antibodies, 
etc., where the binding partner is conjugated to a detectable 
label. The label may be conjugated to one or both of the 
primers. Alternatively, the pool of nucleotides used in the 
an antibody specific to the CIC channel ligand or CIC chan-
nel, as long as the antibody does not disrupt CIC channel 
ligand-CIC channel binding. Alternatively, the ion channel 
polypeptide used may be a fusion protein which provides for 
specific immunoprecipitation of the fusion partner, an enzy-
matic detection, a fluorescent signal (e.g., a green fluorescent 
protein). The ion channel polypeptide can be labeled with any 
detectable label, as described below. The ion channel 
polypeptide can be attached, directly or through a linker, to an 
insoluble support (e.g., polystyrene beads, magnetic beads, 
and the like), thereby providing a means for separating scor-
pion toxin family polypeptide-ion channel/receptor com-
plexes from the biological sample, and subsequently detect-
ing the presence of and/or measuring the amount (level) of 
scorpion venom toxin polypeptide. The latter method can also 15 
be used to identify new proteins that bind to GaTx2, such as 
other ion channels/receptors. 
10 amplification is labeled, so as to incorporate the label into the 
amplification product. 
Binding of CIC channel ligand to the ion channel may also 
be detected by monitoring ion channel activity, using meth-
ods such as electrophysiology (two electrode voltage clamp 20 
or single electrode patch clamp), guanidinium ion flux assays, 
toxin-binding assays, and Fluorometric Imaging Plate Reader 
(FLIPR) assays. (See, e.g., Sullivan, et al. (1999) Methods 
Mal. Biol. 114:125 133; Siegel and Isacoff (1997) Neuron 
19:1 20; and Lopatin, et al. (1998) Trends Pharmacol. Sci. 25 
19:395 398.) 
2. Methods of Detecting GaTx2 mRNA in a Biological 
Sample 
One embodiment provides methods for detecting the pres-
ence of CIC channel ligand mRNA in a biological sample. 30 
The methods can be used, for example, to assess whether a 
test compound affects CIC channel ligand gene expression, 
directly or indirectly. 
An exemplary method generally includes: 
a) contacting the sample with a CIC channel ligand-encod- 35 
ing polynucleotide under conditions which allow hybridiza-
tion; and 
b) detecting hybridization, if any. 
Detection of hybridization, when compared to a suitable 
control, is an indication of the presence in the sample of a CIC 40 
channel ligand-encoding polynucleotide, for example a 
GCaTx2-encoding polynucleotide. Appropriate controls 
include, for example, a sample which is known not to contain 
CIC channel ligand-encoding polypeptide mRNA, and use of 
C. Research Tools 
The disclosed peptide CIC channel ligands can be used to 
investigate CIC channel structure and function. For example, 
GaTx2 can be used as a structural probe of the CIC-2 or its 
domains, or any other member of the CIC channel superfam-
ily, or their domains. For example, GaTx2, or a derivative of 
GaTx2, can be used to stabilize the conformation of CIC-2 
protein, or its domains, or any other member of the CIC 
channel superfamily, or their domains, in crystallization 
experiments. 
Additionally, GaTx2, or a derivative ofGaTx2, can be used 
to isolate CIC-2, or its domains, or any other member of the 
CIC channel superfamily, or their domains, by way of affinity 
chromatography wherein GaTx2, or a derivative ofGaTx2, is 
coupled to a solid support. 
One embodiment provides a method for isolating CIC-2 
protein by attaching a peptide having at least 97% sequence 
identity to SEQ ID NO: 1 to a solid support and contacting the 
peptide on the solid support with a sample containing CIC2 
under conditions promoting the interaction of the peptide 
with CIC-2 to retain CIC-2. Conditions that promote interac-
tion between the peptide and CIC-2 include physiological 
conditions of pH, salt concentration, and temperature. The 
solid support can be washed with neutral buffer to remove 
non-specifically bound components. Next, CIC-2 is eluted 
from the solid support for example by increasing the salt 
concentration in the elution buffer. 
V. Screening Assays 
Another embodiment provides screening methods for 
identifying agents which modulates CIC channel ligand-CIC 
channel binding activity such as GaTx2-CIC channel binding 
activity, methods for identifying agents which modulate 
GaTx2-CIC channel interaction, methods for identifying 
agents which modulate a level of GaTx2 in a cell, and meth-
ods for identifying agents which modulate a level of GaTx2 
mRNA in a cell. 
As used herein, the term "modulate" encompasses 
"increase" and "decrease". Of particular interest are agents 
which modulate GaTx2-CIC channel binding activity, and/or 
which modulate GaTx2-ion channel interaction, and/or 
which modulate a level of CIC channel ligand in a cell, and/or 
which modulate a level of GaTx2 mRNA in a cell. Such 
agents are of interest as candidates for treating diseases or 
a labeled polynucleotide of the same "sense" as a CIC channel 45 
ligand mRNA. Conditions which allow hybridization are 
known in the art, and have been described in more detail 
above. Detection can be accomplished by any known method, 
including, but not limited to, in situ hybridization, PCR, RT-
PCR, and "Northern" or RNA blotting, or combinations of 50 
such techniques, using a suitably labeled CIC channel ligand 
polynucleotide. A variety oflabels and labeling methods for 
polynucleotides are known in the art and can be used in the 
assay methods of the invention. Specific hybridization can be 
determined by comparison to appropriate controls. 55 disorders associated with ion channels, including, but not 
limited to those associated with chloride channels (e.g., exci-
totoxic neuronal injury, epilepsy, renal tubular disorders, Bar-
tter' s syndrome, cystic fibrosis, osteopetrosis, Angleman or 
Methods using PCR amplification can be performed on the 
DNA from a single cell, although it is convenient to use at 
least about 105 cells. The use of the polymerase chain reaction 
is described in Saiki et al. (1985) Science 239:487, and a 
review of current techniques may be found in Sambrook, et al. 60 
Molecular Cloning: A Laboratory Manual, CSH Press 1989, 
pp. 14.2314.33. A detectable label may be included in the 
amplification reaction. Suitable labels include fluoro-
chromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, 
Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluo- 65 
rescein (6-FAM), 2',7'-dimethoxy-4=,5=-dichloro-6-car-
boxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 
Prader-Willi, upregulation of chloride channels in glioma 
cells, etc.), sodium channels (e.g., Hyperkalemic periodic 
paralysis, hypokalemic periodic paralysis, congenital 
Paramyotonia, Myotonia Fluctuans, Myotonia Permanens, 
Acetazolamide-responsive myotonia, malignant hyperther-
mia, nerve injury, epilepsy, various heart diseases, thyroid, 
endocrine, etc.). 
The terms "agent'', "substance" and "compound" are used 
interchangeably herein. Candidate agents encompass numer-
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b) measuring CIC channel binding activity of the CIC 
channel ligand in the presence of the substance. 
An increase or a decrease in CIC channel binding activity in 
comparison to CIC channel binding activity in a suitable 
control (e.g., a sample including CIC channel ligand and an 
CIC channel in the absence of the substance being tested) is an 
indication that the substance modulates a CIC charmel bind-
ing activity of the CIC channel ligand. 
Methods for practicing such assays are known to those of 
skill in the art. (See, e.g., Mishina et al. (1985) Nature 313: 
364 369; and Noda, et al. Nature 322:836 828.) For example, 
ion channel activity may be measured by methods such as 
electrophysiology (two electrode voltage clamp or single 
electrode patch clamp), guanidinium ion flux assays, toxin-
ous chemical classes, typically synthetic, semi-synthetic, or 
naturally-occurring inorganic or organic molecules. Candi-
date agents may be small organic compounds having a 
molecular weight of more than 50 and less than about 2,500 
daltons. Candidate agents may comprise functional groups 
necessary for structural interaction with proteins, particularly 
hydrogen bonding, and typically include at least an amine, 
carbonyl, hydroxyl or carboxyl group, and may contain at 
least two of the functional chemical groups. The candidate 
agents may comprise cyclical carbon or heterocyclic struc- 10 
tures and/or aromatic or polyaromatic structures substituted 
with one or more of the above functional groups. Candidate 
agents are also found among biomolecules including pep-
tides, saccharides, fatty acids, steroids, purines, pyrimidines, 
derivatives, structural analogs or combinations thereof. 
Candidate agents are obtained from a wide variety of 
sources including libraries of synthetic or natural com-
pounds. For example, numerous means are available for ran-
dom and directed synthesis of a wide variety of organic com-
pounds and biomolecules, including expression of 20 
randomized oligonucleotides and oligopeptides. Alterna-
tively, libraries of natural compounds in the form of bacterial, 
fungal, plant and animal extracts are available or readily 
produced. Additionally, natural or synthetically produced 
libraries and compounds are readily modified through con- 25 
ventional chemical, physical and biochemical means, and 
may be used to produce combinatorial libraries. Known phar-
macological agents may be subjected to directed or random 
chemical modifications, such as acylation, alkylation, esteri-
fication, amidification, etc. to produce structural analogs. 30 
Furthermore, pharmacophores may be designed based on the 
structural aspects of the ion charmel/receptor binding inter-
faces of scorpion venom toxin polypeptides. 
15 binding assays, and Fluorometric Imaging Plate Reader 
(FLIPR) assays. (See, e.g., Sullivan, et al. (1999) Methods 
Mal. Biol. 114: 125 133; Siegel and Isacoff (1997) Neuron 
19: 1 20; and Lopatin, et al. (1998) Trends Pharmacol. Sci. 
Where the screening assay is a binding assay, one or more 
of the molecules may be joined to a label, where the label can 35 
directly or indirectly provide a detectable signal. Various 
labels include radioisotopes, fluorescers, chemiluminescers, 
enzymes, specific binding molecules, particles, e.g. magnetic 
particles, and the like. Specific binding molecules include 
pairs, such as biotin and streptavidin, digoxin and antidigoxin 40 
etc. For the specific binding members, the complementary 
member would normally be labeled with a molecule that 
provides for detection, in accordance with known procedures. 
A variety of other reagents may be included in the screen-
ing assay. These include reagents like salts, neutral proteins, 45 
e.g. albumin, detergents, etc that are used to facilitate optimal 
protein-protein binding and/or reduce non-specific or back-
ground interactions. Reagents that improve the efficiency of 
the assay, such as protease inhibitors, nuclease inhibitors, 
anti-microbial agents, etc. may be used. The components can 50 
be added in any order that provides for the requisite binding. 
Incubations are performed at any suitable temperature, typi-
cally between 4° C. and 40° C. Incubation periods are 
selected for optimum activity, but may also be optimized to 
facilitate rapid high-throughput screening. Typically between 55 
0.1 and 1 hour will be sufficient. 
1. Methods for Identifying Agents that Modulate GaTx2-
Ion Channel Binding Activity 
One embodiment provides methods of identifying agents 
which modulate CIC channel binding activity of CIC channel 60 
ligands. The term "modulate" encompasses an increase or a 
decrease in the measured CIC channel ligand-CIC channel 
binding activity when compared to a suitable control. 
The method generally comprises: 
a) contacting a substance to be tested with a sample con- 65 
taining a CIC channel ligand such as GaTx2 and a chloride ion 
channel such as a CIC channel; and 
19:395 398.) 
An "agent which modulates CIC channel-CIC channel 
ligand binding activity", as used herein, describes any mol-
ecule, e.g. synthetic or natural organic or inorganic com-
pound, protein or pharmaceutical, with the capability of alter-
ing CIC channel binding activity of a CIC channel ligand, as 
described herein. Generally a plurality of assay mixtures are 
run in parallel with different agent concentrations to obtain a 
differential response to the various concentrations. Typically, 
one of these concentrations serves as a negative control, i.e. at 
zero concentration or below the level of detection. Ion chan-
nel binding can be measured as described hereinabove. 
An agent which modulates CIC charmel binding activity of 
a CIC channel ligand increases or decreases the activity at 
least about 10%, at least about 15%, at least about 20%, at 
least about 25%, more preferably at least about 50%, more 
preferably at least about 100%, or 2-fold, more preferably at 
least about 5-fold, more preferably at least about 10-fold or 
more when compared to a suitable control. 
2. Methods of Detecting Agents which Modulate a Level of 
GaTx2 mRNA and/or Polypeptide 
A wide variety of cell-based assays may be used for iden-
tifying agents which modulate levels of CIC channel ligand 
polypeptide mRNA, using, for example, a mammalian cell 
transformed with a construct including a CIC charmel-encod-
ing cDNA such that the cDNA is overexpressed, or, alterna-
tively, a construct including a CIC channel gene promoter 
operably linked to a reporter gene. 
Accordingly, one embodiment provides a method for iden-
tifying an agent, particularly a biologically active agent, that 
modulates a level of CIC charmel ligand expression in a cell, 
the method including: combining a candidate agent to be 
tested with a cell comprising a nucleic acid which encodes a 
CIC charmel ligand; and determining the effect of said agent 
on CIC charmel ligand expression. A modulation of CIC chan-
nel ligand expression levels includes increasing the level and 
decreasing the level of CIC channel ligand mRNA and/or 
scorpion venom toxin encoded by the scorpion venom toxin 
polynucleotide when compared to a control lacking the agent 
being tested. An increase or decrease of about 1.25-fold, 
usually at least about 1.5-fold, usually at least about 2-fold, 
usually at least about 5-fold, usually at least about 10-fold or 
more, in the level (i.e., an amount) of CIC channel ligand 
mRNA and/or polypeptide following contacting the cell with 
a candidate agent being tested, compared to a control to which 
no agent is added, is an indication that the agent modulates 
CIC channel ligand expression. 
An agent being tested for its effect on CIC channel ligand 
expression is assessed for any cytotoxic activity it may exhibit 
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toward the cell used in the assay, using well-known assays, 
such as trypan blue dye exclusion, an MTT ([3-( 4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide]) 
assay, and the like. Agents that do not exhibit cytotoxic activ-
ity are considered candidate agents. 
The cells used in the assay are usually mammalian cells, 
including, but not limited to, rodent cells and human cells. 
The cells may be primary cell cultures. 
36 
invention to identify an agent which modulates CIC channel 
ligand mRNA level in a cell, including, but not limited to, a 
PCR, such as a PCR employing detectably labeled oligo-
nucleotide primers, and any of a variety of hybridization 
assays. Similarly, CIC channel ligand levels can be measured 
using any standard method, several of which have been 
described herein, including, but not limited to, an immunoas-
say such as ELISA, for example an ELISA employing a 
detectably labeled antibody specific for a CIC channel ligand. Scorpion venom toxin family polypeptide mRNA and/or 
polypeptide whose levels are being measured can be encoded 
by an endogenous scorpion venom toxin polynucleotide, or 
the scorpion venom toxin polynucleotide can be one that is 
comprised within a recombinant vector and introduced into 
the cell, i.e., the CIC channel ligand mRNA and/or polypep-
tide can be encoded by an exogenous scorpion venom toxin 
polynucleotide. For example, a recombinant vector may com-
prise an isolated CIC channel ligand transcriptional regula-
tory sequence, such as a promoter sequence, operably linked 
10 VI. Preparation of Antivenom and Antibodies 
Identification of potent components is an important first 
step in designing and obtaining effective antivenom. Antibod-
ies raised against the critical toxic components have the 
potential to block the toxic effects and reduce the pain asso-
to a reporter gene (e.g., ~-galactosidase, CAT, luciferase, or 
other gene that can be easily assayed for expression). In these 
embodiments, the method for identifying an agent that modu-
lates a level of CIC channel ligand expression in a cell, com-
prises: combining a candidate agent to be tested with a cell 
comprising a nucleic acid which comprises a scorpion venom 
toxin gene transcriptional regulatory element operably linked 
to a reporter gene; and determining the effect of said agent on 
reporter gene expression. A recombinant vector may com-
prise an isolated CIC channel ligand transcriptional regula-
tory sequence, such as a promoter sequence, operably linked 
15 ciated with the scorpion envenomation. Antibodies that spe-
cifically bind to scorpion venom toxin polypeptides, in par-
ticular to GaTx2 are produced by: 1) immunization of non-
human animals with the isolated proteins and production of 
hybridomas; and 2) identification of antibodies that specifi-
20 cally bind scorpion venom toxin polypeptides (e.g., by 
screening hybridoma supematants with scorpion venom 
toxin). Each of these steps is described below. 
Antibodies specific to GaTx2 are produced by immunizing 
a non-human mammal (e.g., murine, rodentia, lagomorpha, 
25 ovine, porcine, bovine, etc.) with isolated GaTx2. Immuni-
zation and hybridoma production with the scorpion venom 
toxin polypeptide can be accomplished according to conven-
tional methods well known in the art. The immunized animal 
to sequences coding for a CIC channel ligand; or the tran- 30 
scriptional control sequences can be operably linked to cod-
ing sequences for a scorpion venom toxin fusion protein 
comprising CIC channel ligand fused to a polypeptide which 
facilitates detection. In these embodiments, the method com-
prises combining a candidate agent to be tested with a cell 35 
comprising a nucleic acid which comprises a scorpion venom 
toxin gene transcriptional regulatory element operably linked 
to a CIC channel ligand-coding sequence; and determining 
the effect of said agent on CIC channel ligand expression, 
which determination can be carried out by measuring an 40 
amount of CIC channel ligandmRNA, CIC channel ligand, or 
scorpion venom toxin fusion polypeptide produced by the 
cell. 
is an immunocompetent, non-human mammalian host, 
including murine, rodentia, lagomorpha, ovine, porcine, 
bovine, etc., which is immunized with scorpion venom toxin 
polypeptide isolated as described above. The choice of a 
particular host is primarily one of convenience. Immuniza-
tions are generally performed in accordance with conven-
tional techniques. 
Either monoclonal or polyclonal antibodies, preferably 
monoclonal antibodies (MAbs ), are produced from the 
immunized animal. Polyclonal antisera may be harvested 
from serum in accordance with conventional methods after 
completion of the immunization schedule. For production of 
MAbs, lymphocytes are harvested from the appropriate lym-
phoid tissue, e.g. spleen, draining lymph node, etc., and fused 
with an appropriate fusion partner, usually a myeloma line, 
producing a hybridoma secreting a specific monoclonal anti-
45 body. Methods for hybridoma production are well known in 
the art (see, e.g., Antibodies, A Laboratory Manual, Harlow & 
Lane eds., (1988) Cold Spring Harbor Press). 
Cell-based assays generally comprise the steps of contact-
ing the cell with an agent to be tested, forming a test sample, 
and, after a suitable time, assessing the effect of the agent on 
CIC channel ligand expression. A control sample comprises 
the same cell without the candidate agent added. CIC channel 
ligand expression levels are measured in both the test sample 
and the control sample. A comparison is made between CIC 
channel ligand expression level in the test sample and the 
control sample. CIC channel ligand expression can be 
assessed using conventional assays. For example, when a 
mammalian cell line is transformed with a construct that 
results in expression of CIC channel ligand, CIC channel 
ligand mRNA levels can be detected and measured, as 
described above, or CIC channel ligand levels can be detected 
and measured, as described above. A suitable period of time 
for contacting the agent with the cell can be determined 
empirically, and is generally a time sufficient to allow entry of 60 
the agent into the cell and to allow the agent to have a mea-
surable effect on CIC channel ligand mRNA and/or polypep-
tide levels. Generally, a suitable time is between 10 minutes 
and 24 hours, more typically about 18 hours. Methods of 
measuring CIC channel ligand mRNA levels are known in the 
art, several of which have been described above, and any of 
these methods can be used in the methods of the present 
The antibodies and MAbs can be modified in any of a 
variety of ways, with the proviso that the modified MAbs 
50 retain substantially specific binding to the original antigen 
(e.g., to the original scorpion venom toxin polypeptide). The 
ability of such modified antibodies to specifically and sensi-
tively bind their original antigen can be assessed in in vitro 
assays as described herein (e.g., to assess binding of the 
55 modified antibodies to scorpion venom toxin in cytospin 
preparations, to scorpion venom toxin cell-specific polypep-
tides in ELISA assays, etc.). Such screening is routine and, 
with the guidance provided herein, within the skill of the 
ordinarily skilled artisan. 
Modified antibodies contemplated by the present invention 
include those produced using biochemical, chemical, or 
recombinant DNA techniques. For example, antibody frag-
ments, such as Fv, F(ab')2 and Fab may be prepared from the 
antibodies of the invention by cleavage of the intact protein, 
65 e.g., by protease or chemical cleavage. Alternatively, a trun-
cated gene is designed. For example, a chimeric gene encod-
ing a portion of the F(ab')2 fragment would include DNA 
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sequences encoding the CH 1 domain and hinge region of the 
H chain, followed by a translational stop codon to yield the 
truncated molecule. Preferably, such antibody fragments 
retain antigen avidity and/or affinity that is substantially the 
same as the original antibody from which they are derived. 
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channel ligand-encoding polynucleotides in a biological 
sample. Procedures using these kits can be performed by 
clinical laboratories, experimental laboratories, medical 
practitioners, or private individuals. The kits for detecting a 
CIC charmel ligand include a moiety that specifically binds 
scorpion venom polypeptide, including, but not limited to, 
CIC channel ligand-specific antibody and an ion channel 
polypeptide. The kits for detecting a CIC channel ligand-
encoding polynucleotide include a moiety that specifically 
hybridizes to a CIC channel ligand-encoding polynucleotide. 
The kit may optionally provide additional components that 
are useful in the procedure, including, but not limited to, 
buffers, developing reagents, labels, reacting surfaces, means 
for detections, control samples, standards, instructions, and 
The subject antibodies may also be produced as a single 
chain, instead of the normal multimeric structure. Single 
chain antibodies are described in Jost et al. (1994) J. Biol. 
Chem. 269:26267 73, and others. DNA sequences encoding 
the variable region of the heavy chain and the variable region 10 
of the light chain are ligated to a spacer encoding at least 
about four amino acids of small neutral amino acids, includ-
ing glycine and/or serine. The protein encoded by this fusion 
allows assembly of a functional variable region that retains 
the specificity and affinity of the original antibody. 15 interpretive information. 
The antibodies may also be humanized. Methods of 
humanizing antibodies are well known in the art. The human-
ized antibody may be the product of an animal having trans-
genic human immunoglobulin (lg) constant region genes (see 
for example, WO 90/10077 and WO 90/04036). Alterna- 20 
tively, the antibody of interest may be engineered by recom-
binant DNA techniques to substitute the CHu CH2 , CH3 , 
hinge domains, and/or the framework residues with the cor-
responding human sequence (see WO 92/02190). Humanized 
antibodies are of particular interest for in vivo use in humans. 25 
The antibodies may also be used to produce chimeric anti-
bodies. The use of lg cDNA for construction of chimeric lg 
genes is known in the art (Liu et al. (1987) Proc. Natl. Acad. 
Sci. 84:3439; Liu et al. (1987)J. Immunol. 139:3521). mRNA 
is isolated from a hybridoma or other cell producing the 30 
antibody and used to produce cDNA. The cDNA of interest 
may be amplified by the polymerase chain reaction using 
specific primers (U.S. Pat. Nos. 4,683,195 and 4,683,202). 
Alternatively, a library is made and screened to isolate the 
sequence of interest. The DNA sequence encoding the vari- 35 
able region of the antibody is then fused to human constant 
region sequences. The sequences of human constant regions 
genes may be found in Kabat et al. (1991) Sequences of 
Proteins of Immunological Interest, N.I.H. publication no. 91 
3242. Human C region genes are readily available from 40 
known clones. The chimeric, humanized antibody is then 
expressed by conventional methods. 
Expression vectors for use in modification of the antibod-
ies of the invention are well known in the art and include 
plasmids, retroviruses, YACs, EBY derived episomes, and the 45 
like, For example, where the scorpion venom toxin polypep-
tide antibody is to be modified to provide a human antibody 
heavy and/or light chain constant region, a convenient vector 
is one that encodes a functionally complete human CH or CL 
Pharmaceutical kits for the treatment of scorpion stings, 
which include one or more containers containing a pharma-
ceutical composition including a therapeutically effective 
amount of a GaTx2 polypeptide inhibitor compound or anti-
body to a GaTx2 polypeptide. Such kits can further include, if 
desired, one or more of various conventional pharmaceutical 
kit components, such as, for example, containers with one or 
more pharmaceutically acceptable carriers, additional con-
tainers, etc., as will be readily apparent to those skilled in the 
art. Printed instructions, either as inserts or as labels, indicat-
ing quantities of the components to be administered, guide-
lines for administration, and/or guidelines for mixing the 
components, can also be included in the kit. 
The disclosure is further defined in the following 
Examples. It should be understood that these Examples, 
while indicating preferred embodiments, are given by way of 
illustration only, From the above discussion and these 
Examples, one skilled in the art can ascertain the essential 
characteristics of the various embodiments, and without 
departing from the spirit and scope thereof, can make various 
changes and modifications to adapt to various usages and 
conditions. 
EXAMPLES 
Example 1 
Venom Preparation and Toxin Purification 
Dried whole venom (Latoxan, France; or Sigma Chemical 
Co., Chicago, Ill.) was prepared at a stock concentration of2 
mg/mL in the appropriate bath solution (see below) for elec-
trophysiological recording. The mucous portion of the venom 
was removed by processing the venom with four strokes in a 
50 Potter-Elvehjem tissue grinder, followed by centrifugation at 
6000xg for 30 minutes to pellet the mucous component. The 
supernatant was passed through a 10 kDa molecular weight 
cut-off filter (Millipore Corp; Bedford, Mass.) by centrifuga-
tion at 2000xg for 40 minutes. The resulting partially frac-
lg sequence, with appropriate restriction sites engineered so 
that any VH or VL sequence can be easily inserted and 
expressed. In such vectors, splicing usually occurs between 
the splice donor site in the inserted J region and the splice 
acceptor site preceding the human C region, and also at the 
splice regions that occur within the human CH exons. Poly-
adenylation and transcription termination occur at native 
chromosomal sites downstream of the coding regions. The 
resulting chimeric antibody may be joined to any strong pro-
moter, including retroviral LTRs, e.g. SV-40 early promoter, 
(Okayama et al. (1983) Mal. Cell. Biol, 3:280), Rous sarcoma 60 
virus LTR (Gorman et al. (1982) Proc. Natl. Acad. Sci. 
79:6777), and Moloney murine leukemia virus LTR (Gross-
chedl et al. (1985) Cell 41:885); native lg promoters, etc. 
VII. Kits 
The detection methods discussed above can be provided as 
part of a kit. Thus, one embodiment provides kits for detect-
ing the presence and/or a level of CIC charmel ligand or CIC 
55 tionated venom (Lqh pf-venom) was then distributed into 1 
mL aliquots and stored at -80° C. For RP-HPLC, venom was 
prepared at a concentration of 5 mg/mL in solution that con-
tained (in mM): 150 NMDG-Cl, 5 MgCl2 , 10 TES, and 10 
Tris•EGTA, pH 7.5. 
Reversed-phase HPLC was performed on Lqh pf-venom 
prepared as described above. RP-HPLC was performed on a 
Waters 1525 binary HPLC coupled to a Waters 2487 dual 
wavelength absorbance detector, utilizing a Zorbax 300SB-
C3 column (4.6 mmx250 mm) or Zorbax SB-C18 column 
65 (4.6 mmx250 mm). 
Venom components were separated into fractions contain-
ing only components smaller than 10 kDa. Each fraction was 
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tested for inhibition of ClC-2 currents using two-electrode 
voltage clamp (TEVC). With initial separation performed 
using a C3 colunm, the fraction collected from 0-10 minutes, 
Fraction A, retained activity similar to Lqh pf-venom (FIG. 
lA, 45.7±6% inhibition, fraction concentration 0.1 mg/mL 5 
equivalent, n=3, p=0.01). The brief retention time of the 
active component on the C3 colunm suggests that the toxin is 
very hydrophilic. 
Final isolation and purification of the active toxin was 
achieved through two successive rounds ofRP-HPLC using a 10 
Cl8 colunm, as surmnarized in FIGS. lB and lC. The iso-
lated toxin, peak #3, eluted at -12 minutes and was sufficient 
to fully recapitulate the activity observed for Lqh pf-venom 
when diluted to the same equivalent concentration 
(64.2±5.3% inhibition at 0.1 mg/mL equivalent, n=4, 15 
p=0.025). Amino acid analysis performed during protein 
sequencing (see FIG. 2) revealed that this toxin was present at 
very low abundance, with 0.1 mg/mL venom containing this 
toxin at a concentration of only I 0 nM. A preliminary dose-
response curve constructed using native purified toxin 20 
showed that the Kn at V M=-160 m Vis only 80 µM (FIG. lD). 
Example 2 
Proteomic Characterization ofGaTx2 25 
The active toxin was analyzed via MALD I-MS at the Geor-
gia Institute of Technology Bioanalytical Mass Spectrometry 
Facility. Edman degradation was performed at the Emory 
University Microchemical andProteomics Facility. Sequence 30 
analysis of the natural and modified (reduced and alkylated) 
peptides was performed using Applied Biosystems model 
Procise-cLC automated protein sequencer (Applied Biosys-
tems 49lcLC CLC capillary protein sequencing system; Fos-
ter City, Calif.) using the manufacturer's cycles with slight 35 
modifications. Prior to sequencing, natural and modified 
samples were de-salted and purified via RP-HPLC. 
Peak #3 was then subjected to MALDI-TOF mass spectro-
metric analysis to determine the molecular mass of the intact 
compound, and to ensure that the collected chromatographic 40 
peak contained only one component. This analysis revealed 
that peak #3 contained one component with an apparent mass 
of3.19 kDa (FIG. 2A); a doubly charged species of the same 
component was also apparent. 
Due to the lack of fragmentation of the intact toxin via 45 
MS/MS, Edman degradation was performed on the isolated 
toxin in order to obtain the primary sequence. Reduction of 
the active toxin with DTT followed by carboxamidomethy-
lation induced a mass shift (3191.6 to 3539.5 kDa), as deter-
mined by MALDI-MS, that corresponded to the modification 50 
of 6 cysteine residues, indicating that the intact protein con-
tained 3 disulfide linkages. The reduced/carboxamidomethy-
lated toxin was then sequenced using Edman degradation and 
amino acid analysis, providing the complete primary 
sequence: 1VSCEDCPDHCSTQKARAKCDNDKCV- 55 
CEPI29 (SEQ ID NO: I). The identity of the C-terminal resi-
due, 129, was determined by amino acid analysis. This 
sequence was confirmed by Edman sequencing of Lys-C 
protease digested, reduced/carboxamidomethylated toxin. 
The toxin was isolated from venom on three separate occa- 60 
sions, as confirmed by MS analysis of the active fraction from 
these isolations. Sequence comparisons revealed that this 
primary sequence exactly matches the sequence of 
Leiuropeptide II (LPII), a peptide isolated in 1997 from the 
same scorpion which was not shown to have any lethal effects 65 
when injected into mouse brain or insects (Buisine, E. et al. 
(1997) J. Pept. Res. 49, 545-555). In fact, LPII was proposed 
40 
to be a potassium channel inhibitor based on cysteine align-
ment and the presence of a lysine residue at position 18, which 
is in the same position in the folded protein as the critical 
lysine (Lys27) of charybdotoxin. Lysine 27 is part of a critical 
dyad, with its partner being an aromatic residue located -6 A 
away (Mouhat, S. eta!. (2005)J. Pept. Sci. 11, 65-68). InLPII, 
however, this aromatic residue is absent. No target for LPII 
has ever been identified. Because this toxin actually inhibits a 
chloride channel, instead of a K+ channel as originally pro-
posed, it was renamed to GaTx2 to avoid confusion. GaTx2 is 
also very similar in primary sequence to a number of other 
toxins; the most relevant are shown in FIG. 2B. Of these 
toxins, only four have been shown to be active against ion 
channels: neurotoxin POI, which is weakly toxic (Zerrouk, H. 
et al. (1996) Int. J. Pept. Protein Res. 48, 514-521), scylla-
toxin, which inhibits Ca2+ -activated K+ (KcJ channels 
(Chicchi, G. G. et al. (1988) J. Biol. Chem. 263, 10192-
10197), and maurotoxin and OdKI, both of which inhibit 
Kvl.2 (Kharrat, R., et al. (1996) European journal of bio-
chemistry/FEES 242, 491-498) and (Abdel-Mottaleb, Y. et al. 
(2006) FEES Lett 580, 6254-6258). 
Example 3 
Homology Model ofGaTx2 
A homology model of GaTx2 was created based on the 
neurotoxin POI NMR structure (Blanc, E. et al. (1996) Pro-
teins 24, 359-369) in order to make structural comparisons of 
GaTx2 to other known scorpion toxins (FIG. 2C middle). The 
homology model of GaTx2 was created using the Modeller 
8v2 program, using neurotoxin POI as the template structure. 
The GaTx2 homology model was then minimized via a 5 ps, 
2500 step simulation with NAMDv2 utilizing the charmm22 
force field. Prior to minimization, disulfide bridges were 
patched in order to ensure that the disulfide bonds remained 
intact during energy minimization. 
This model predicts that GaTx2 is composed of2 ~-strands 
and one a-helix, which are connected via 3 disulfide bonds. 
This basic fold is highly conserved among numerous toxins 
isolated from various scorpion species (Rodriguez de la Vega, 
R. C. & Possani, L. D. (2004) Toxicon 43, 865-875). 
GaTx2 is noticeably more compact than both scyllatoxin 
(FIG. 2C left) and chlorotoxin (FIG. 2C right), a toxin iso-
lated from a related scorpion that is thought to inhibit an 
unidentified c1- channel in rat brain when reconstituted into 
lipid bilayers. The primary and secondary structures of 
GaTx2 are also very different from GaTxl, a recently isolated 
peptide inhibitor active against the CFTR c1- channel (Fuller, 
M. D., Thompson, C.H., Pohl, J., Kubanek, J., & McCarty, N. 
A. (2007) Biophys. J. 92 Supplement, 275a, Abstract, 1297-
pos). GaTx2 is -400 Da smaller than GaTxl and has one 
fewer disulfide bond. GaTx2 has a calculated pl of just 4.51, 
which accounts for the large negative electrostatic potential 
that is associated with the protein and could possibly explain 
the lack of activity against cation channels. 
Example 4 
Inhibition ofClC-2 by Synthetic GaTx2 
GaTx2 was produced via solid-phase chemical synthesis, 
as has been done for many other peptide inhibitors (Chang, N. 
S. et al. (1998) Biochemistry 37, 4407-4419; Hui, K. et al. 
(2003) J. Gen. Physiol. 122, 63-79). The folded synthetic 
toxin shows the same mass as the purified native toxin, indi-
cating that no post-translational modifications were associ-
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ated with the native toxin other than the three disulfide bonds 
(FIGS. SA and B). Activity of synthetic GaTx2 was deter-
mined by recording from inside-out multi-channel patches. 
Xenopus oocytes were isolated as previously described and 
incubated at 18° C. in a modified Liebovitz's L-15 medium 5 
(pH 7 .5) with a cocktail of antibiotics (gentamicin, penicillin, 
streptomycin) and HEPES. CRNA was prepared from rabbit 
ClC-2 using a construct in pSportl, donated by H. C. Hartzell 
(Emory University, Atlanta, Ga.). For two-electrode voltage 
clamp experiments (TEYC), oocytes were injected with 2.5- 10 
25 ng ofClC-2 cRNA, 0.06-1 ng Sh13-IR cRNA, or 50-100 
ng GABAcrho subunit cRNA. For patch recordings, oocytes 
were injected with 0.5-2 ng ClC-2 cRNA. Data were collected 
at room temperature 2-5 days post injection. Methods for 15 
animal handling are in accordance with the NIH guidelines 
and the protocol was approved by the Animal Use and Care 
Committee of the Georgia Institute of Technology. 
Inside-out multi-channel and single channel patch clamp 
experiments were performed as previously described (Fuller, 20 
M. D. et al. (2005) Biophys. J. 89, 3960-3975). All data were 
recorded to DAT tape at 10 kHz and were subsequently fil-
tered at 100 Hz and acquired by computer at 500 Hz. For 
inside-out patches in the presence of toxin, the toxin was 
backfilled into the pipette and allowed to diffuse to the surface 25 
of the patch. Unless otherwise stated, all single channel traces 
depicted in the figures were recorded at V M=-100 m V. For all 
electrophysiological data shown, the horizontal dashed line 
indicates the zero-current level. 
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Example 5 
Effect ofGaTx2 on Single ClC-2 Channels 
Peptide toxins may either inhibit channels by acting as pore 
blockers, which fully or partially occlude the pore, or by 
acting as gating modifiers, making it more difficult for the 
channel to open (McDonough, S. I. (2003) in Calcium Chan-
nel Pharmacology, ed. McDonough, S. I. Kluwer-Academic-
Plenum Publishing, New York). In order to determine if 
GaTx2 alters the single channel conductance of ClC-2, all-
points amplitude histograms were created from segments of 
records with only 1-2 open channels, in the absence and 
presence of GaTx2. In the presence of GaTx2, the single 
protopore amplitude at -100 mV was unchanged from con-
trol (0.25±0.01 pA vs, 0.26±0.01 pA, n 3, p=0.45) (FIG. 4A) 
as measured from the difference between 01 and 02 from the 
amplitude histograms created from 2-minute sections of 
record in the absence and presence of toxin. This suggests that 
GaTx2 does not induce partial conductances, although this 
does not discount the possibility of inhibition via a pore block 
mechanism. 
Patch clamp experiments were performed with either one 
or two channels in the patch and 20 pM GaTx2 backfilled into 
the pipette. Measuring channel activity as NP dN, it was 
observed that NP dN was reduced by 59.5±8% (FIG. 4D, 
n=2) at -100 m V, which is consistent with the reduction of 
window current observed in multichannel patches for this 
concentration of toxin (FIG. 3B). Some toxins act via a pore 
For experiments to construct a dose-response curve using 
inhibition of ClC-2 in excised, inside-out multi-channel 
patches, the pipette was backfilled with varying concentra-
tions of synthetic toxin. The pipette was backfilled in such a 
way as to allow 10 minutes of control recording (at V M=-100 
m V or 60 m V), followed by 10 minutes of recording in the 
presence of GaTx2. The average window current from five 
separate four-minute windows in both control and experi-
mental conditions was calculated. 
30 block mechanism by inducing long closed states within a 
channel burst. Expanded bursts (FIG. 4C) show that there 
appear to be no toxin-induced intraburst closures that would 
be consistent with a pore block mechanism. 
In the presence of 20 pM GaTx2, a 7 .67±0.25 fold increase 
35 (FIG. 4E, n 2) in the latency to first opening upon stepping 
from V Ai) to -100 m V was observed, which is consistent with 
a modification of channel gating. 
When no toxin was backfilled into the pipette, no change in 40 
average window current over the course of the experiment 
was observed (FIG. 3A). However, when 2 nM synthetic 
GaTx2 was backfilled into the pipette average window cur-
rents were drastically reduced at the end of the experiment 
(FIG. 3A, B; 80.4±2.0% decrease). These experiments were 45 
repeated with varying concentrations of GaTx2 to obtain a 
dose-response curve, which provided Kn=12 pM and a Hill 
coefficient of 1.39 (FIG. 3B). This high affinity interaction is 
-1 million times stronger than the best characterized inhibi-
tors ofClC channels (Pusch, M. et al. (2000)Mol. Pharmacol. 50 
58, 498-507). 
Previous experiments with Lqh-pf venom indicated that 
inhibition of ClC-2 was voltage-dependent, with improved 
inhibitory efficacy at less hyperpolarizing potentials (Thomp-
son, C. H. et al. (2005) J. Membr. Biol. 208, 65-76). The 55 
experiment shown in FIG. 1 provided a Kn of 80 µM at 
Example 6 
Specificity ofGaTx2 
Peptide toxins are usually highly specific for their respec-
tive targets, although not always perfectly selective. Charyb-
dotoxin (ChTx), for example, is known to inhibit both Kea' 
and K vchannels. Because the Ga Tx2 sequence was originally 
predicted to be a K+ channel inhibitor, experiments were 
performed to determine if this toxin could inhibit the voltage-
gated Drosophila Shaker K+ channel B variant with inactiva-
tion-removed (ShB-IR), by exposing oocytes expressing 
ShB-IR to 20 nM GaTx2, a concentration that strongly inhib-
its ClC-2 currents (FIG. 6A). No inhibition of ShB-IR cur-
rents was observed, indicating that GaTx2 does not interact 
with this channel, although the possibility remains that it may 
inhibit other K+ channels. Activity for GaTx2 against Kvl .2 
K+ channels was tested by exposing oocytes expressing 
Kvl.2 channels to 10 nM GaTx2 (FIG. 6B). No inhibition of 
currents was observed for either peak currents or non-inacti-
vating currents at this toxin concentration, which is 1000 fold 
greater than the Kn for GaTx2 inhibition of ClC-2 channel 
currents. 
Although ClC-2 is a very broadly expressed c1- channel, 
many other c1- channel types are expressed in excitable and 
non-excitable cells. Most inhibitors available for c1- chan-
V M=-160 mV; in contrast, the experiments shown in FIG. 3 
provided a Kn Of 12 pM at V M=-100 m V. This suggests that 
the binding affinity of GaTx2 is voltage-dependent. The 
degree of inhibition of ClC-2 current in multi-channel 60 
patches by 2 pM synthetic GaTx2 at V M=-100 and -60 m V 
were determined (FIG. 3C). At V M=-100 m V, 2 pM toxin did 
not inhibit ClC-2 (4.0±9.9% inhibition, n=ll windows); 
however, at V M=-60 m\7, ClC-2 currents were inhibited 
41.4±4.1 % (n=l 7 windows) by 2 µM toxin, confirming the 
notion that inhibition of ClC-2 by GaTx2 is voltage-depen-
dent. 
65 nels are very non-specific. Experiments were performed to 
determine whether GaTx2 is also capable of inhibiting cur-
rents from ligand-gated chloride channels formed by 
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GABAc receptors, which are unrelated to CIC channels, 
GABA currents were measured both in the absence and pres-
ence ofGaTx2 (FIG. 6C). Comparison of current in the pres-
ence of 10 µM GABA to currents in the presence of 10 µM 
GABA plus 10 nM GaTx2 showed no change (13±9.4% 
increase, p=0.32). GABA-induced c1- currents also did not 
increase upon removal of toxin from the bath solution 
(14±19% increase, p 0.74). This suggests that GaTx2 is not 
capable of inhibiting currents from GABAc receptors. This 
venom had no effect on the skeletal muscle c1- channel 10 
CIC-1. Experiments were performed to determine whether 
synthetic GaTx2 could inhibit CIC-1. Currents in the pres-
ence of toxin were compared to that after washout of toxin in 
order to account for channel rundown. In the presence of 10 15 
nM GaTx2, tail currents at V M=-120 m V from +60 m V were 
1.036±0.012 fold larger than currents after washout of toxin, 
implying no inhibition of CIC-1 (FIG. 6D). 10 nM GaTx2 
also did not inhibit CIC-3 channel mediated currents (FIG. 
6E). Finally, inhibition of CFTR currents was determined by 20 
applying 60 nM cytoplasmically applied GaTx2 and using 
inside-out multi-channel channel patches. In the presence of 
GaTx2, normalized CFTR currents were 0.93±0.03 (n=lO 
<160> NUMBER OF SEQ ID NOS, 12 
<210> SEQ ID NO 1 
<211> LENGTH, 29 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 1 
44 
windows, p 0. 7 4) of control currents. Lqh pf-venom does not 
inhibit CIC-0 (Thompson, C. H. et al. (2005) J. Membr. Biol. 
208, 65-76), and the fraction of venom that includes GaTx2 
does not inhibit CFTR from the extracellular side (Fuller, M. 
D. et al (2004) Am. J. Physiol. 287, (C1328-C1341). This 
suggests that GaTx2 a specific CIC-2 channel inhibitor. 
Example 7 
GaTx2 Synthesis 
Methods for peptide synthesis, purification, and folding 
have been previously described. Solid phase synthesis was 
performed by Fmoc chemistry, using the HBTU/HOBT/DI-
PEA method on an Applied Biosystems 431A synthesizer. 
Oxidative cyclization of the crude linear peptide was per-
formed under equilibrating conditions. The cyclized peptide 
was then purified from the reaction mixture via RP-HPLC and 
characterized by MALDI-MS and analytical HPLC. 
Statistics 
Data are expressed as mean±SEM for n obervations. Dif-
ferences were determined to be significant when p<0.05, 
using paired and unpaired Student's t-tests. 
Val Ser Cys Glu Asp Cys Pro Asp His Cys Ser Thr Gln Lys Ala Arg 
1 5 10 15 
Ala Lys Cys Asp Asn Asp Lys Cys Val Cys Glu Pro Ile 
20 25 
<210> SEQ ID NO 2 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM: Human immunodeficiency virus 
<400> SEQUENCE, 2 
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 3 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Drosophila melanogaster 
<400> SEQUENCE, 3 
Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp 
1 5 10 15 
Lys Lys Cys 
<210> SEQ ID NO 4 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Drosophila melanogaster 
<400> SEQUENCE, 4 
Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp 
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-continued 
1 5 
Lys Lys Cys 
<210> SEQ ID NO 5 
<211> LENGTH, 14 
<212> TYPE, PRT 
10 
<213> ORGANISM: Human immunodeficiency virus 
<400> SEQUENCE, 5 
Ser Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Cys 
1 5 10 
<210> SEQ ID NO 6 
<211> LENGTH, 29 
<212> TYPE, PRT 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (1) .. (29) 
<223> OTHER INFORMATION, Sequence from Leiuropeptide II 
<400> SEQUENCE, 
15 
Val Ser Cys Glu Asp Cys Pro Asp His Cys Ser Thr Gln Lys Ala Arg 
1 5 10 15 
Ala Lys Cys Asp Asn Asp Lys Cys Val Cys Glu Pro Ile 
20 25 
<210> SEQ ID NO 7 
<211> LENGTH, 29 
<212> TYPE, PRT 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 7 
Val Ser Cys Glu Asp Cys Pro Asp His Cys Ser Thr Gln Lys Ala Arg 
1 5 10 15 
Ala Lys Cys Asp Asn Asp Lys Cys Val Cys Glu Pro Lys 
20 25 
<210> SEQ ID NO 8 
<211> LENGTH, 29 
<212> TYPE, PRT 
<213> ORGANISM, Unknown 
<220> FEATURE, 
<223> OTHER INFORMATION, Leuropeptide III 
<400> SEQUENCE, 8 
Val Ser Cys Glu Asp Cys Pro Glu His Cys Ser Thr Gln Lys Ala Gln 
1 5 10 15 
Ala Lys Cys Asp Asn Asp Lys Cys Val Cys Glu Pro Ile 
20 25 
<210> SEQ ID NO 9 
<211> LENGTH, 29 
<212> TYPE, PRT 
<213> ORGANISM, Unknown 
<220> FEATURE, 
<223> OTHER INFORMATION, OdkI 
<400> SEQUENCE, 9 
Val Ser Cys Glu Asp Cys Pro Glu His 
1 5 
Ala Lys Cys Asp Asn Asp Lys Cys Val 
20 25 
Cys Ser Thr Gln Lys 
10 
Cys Glu Ser Val 
Ala 
15 
Arg 
46 
<210> SEQ ID NO 10 
<211> LENGTH, 28 
<212> TYPE, PRT 
47 
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-continued 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 10 
Val Gly Cys Glu Glu Cys Pro Met His Cys Lys Gly Lys Asn Ala Lys 
1 5 10 15 
Pro Thr Cys Asp Asn Gly Val Cys Asn Cys Asn Val 
20 25 
<210> SEQ ID NO 11 
<211> LENGTH, 34 
<212> TYPE, PRT 
<213> ORGANISM: Scorpio maurus palmatus 
<400> SEQUENCE, 11 
Val Ser Cys Thr Gly Ser Lys Asp Cys Tyr Ala Pro Cys Arg Lys Gln 
1 5 10 15 
Thr Gly Cys Pro Asn Ala Lys Cys Ile Asn Lys Ser Cys Lys Cys Tyr 
20 25 30 
Gly Cys 
<210> SEQ ID NO 12 
<211> LENGTH, 31 
<212> TYPE, PRT 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 12 
Ala Phe Cys Asn Leu Arg Met Cys Gln Leu Ser Cys Arg Ser Leu Gly 
1 5 10 15 
Leu Leu Gly Lys Cys Ile Gly Asp Lys Cys Glu Cys Val Lys His 
20 25 30 
48 
We claim: 
1. A method for inhibiting activity of a ClC-2 channel in a 
subject comprising administering to the subject an isolated 
peptide having at least 95% sequence identity to SEQ ID 
NO: 1, wherein the variation in amino acid sequence is due to 
3. The method of claim 1, wherein the isolated peptide is 
40 approximately a 3 .2 kDa peptide. 
a single conservative amino acid substitution, wherein the 
isolated peptide reduces chloride transport through the ClC-2 45 
channel, and wherein the subject has diarrhea-predominant 
inflammatory bowel syndrome or secretory diarrhea. 
2. The method of claim 1, wherein the isolated peptide has 
an apparent dissociation constant ofabout 12 pM for ClC-2 at 
-lOOmV. 
4. The method of claim 1, wherein the isolated peptide has 
a calculated pl of 4.51. 
5. The method of claim 1, wherein the isolated peptide is 
synthetic or recombinant. 
6. The method of claim 1, wherein the isolated peptide is 
administered in a dosage form. 
7. The method of claim 1, wherein the isolated peptide is 
isolated from venom from Leiurus quinquestriatus hebraeus. 
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